<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.3"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Chin Med</journal-id><journal-id journal-id-type="iso-abbrev">Chin Med</journal-id><journal-title-group><journal-title>Chinese Medicine</journal-title></journal-title-group><issn pub-type="epub">1749-8546</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">9338659</article-id><article-id pub-id-type="publisher-id">645</article-id><article-id pub-id-type="doi">10.1186/s13020-022-00645-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Frontier progress of the combination of modern medicine and traditional Chinese medicine in the treatment of hepatocellular carcinoma</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Wei</surname><given-names>Lai</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Wang</surname><given-names>Zeyu</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Jing</surname><given-names>Niancai</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Lu</surname><given-names>Yi</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Jili</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Xiao</surname><given-names>Hongyu</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Guo</surname><given-names>Huanyu</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Shoukun</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Mingjing</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Daqing</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Xiangyan</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Qi</surname><given-names>Wenxiu</given-names></name><address><email>qiwenxiu0517@163.com</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8737-2373</contrib-id><name><surname>Zhang</surname><given-names>Yue</given-names></name><address><email>zhangyuejlcc@163.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.440665.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 641X</institution-id><institution>College of Traditional Chinese Medicine, </institution><institution>Changchun University of Chinese Medicine, </institution></institution-wrap>Changchun, 130117 Jilin China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.440665.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 641X</institution-id><institution>Department of Scientific Research, </institution><institution>Changchun University of Chinese Medicine, </institution></institution-wrap>Changchun, 130117 Jilin China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.440230.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 1789 4901</institution-id><institution>Department of Integrated Chinese and Western Medicine, </institution><institution>Jilin Cancer Hospital, </institution></institution-wrap>Changchun, 130000 Jilin China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.440665.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 641X</institution-id><institution>Northeast Asia Research Institute of Traditional Chinese Medicine, Key Laboratory of Active Substances and Biological Mechanisms of Ginseng Efficacy, Ministry of Education, Jilin Provincial Key Laboratory of Bio-Macromolecules of Chinese Medicine, </institution><institution>Changchun University of Chinese Medicine, </institution></institution-wrap>Changchun, 130117 Jilin China </aff></contrib-group><pub-date pub-type="epub"><day>30</day><month>7</month><year>2022</year></pub-date><pub-date pub-type="pmc-release"><day>30</day><month>7</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>17</volume><elocation-id>90</elocation-id><history><date date-type="received"><day>21</day><month>4</month><year>2022</year></date><date date-type="accepted"><day>20</day><month>7</month><year>2022</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2022</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Hepatocellular carcinoma (HCC, accounting for 90% of primary liver cancer) was the sixth most common cancer in the world and the third leading cause of cancer death in 2020. The number of new HCC patients in China accounted for nearly half of that in the world. HCC was of occult and complex onset, with poor prognosis. Clinically, at least 15% of patients with HCC had strong side effects of interventional therapy (IT) and have poor sensitivity to chemotherapy and targeted therapy. Traditional Chinese medicine (TCM), as a multi-target adjuvant therapy, had been shown to play an active anti-tumor role in many previous studies. This review systematically summarized the role of TCM combined with clinically commonly used drugs for the treatment of HCC (including mitomycin C, cyclophosphamide, doxorubicin, 5-fluorouracil, sorafenib, etc.) in the past basic research, and summarized the efficacy of TCM combined with surgery, IT and conventional therapy (CT) in clinical research. It was found that TCM, as an adjuvant treatment, played many roles in the treatment of HCC, including enhancing the tumor inhibition, reducing toxic and side effects, improving chemosensitivity and prolonging survival time of patients. This review summarized the advantages of integrated traditional Chinese and modern medicine in the treatment of HCC and provides a theoretical basis for clinical research.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s13020-022-00645-0.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Traditional Chinese medicine</kwd><kwd>Hepatocellular carcinoma</kwd><kwd>Combination therapy</kwd><kwd>Adjuvant therapy</kwd><kwd>Chemotherapy</kwd><kwd>Molecular targeted therapy</kwd><kwd>Multidrug resistance</kwd><kwd>Apoptosis</kwd><kwd>Antitumor</kwd><kwd>Overall survival</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100013061</institution-id><institution>Jilin Scientific and Technological Development Program</institution></institution-wrap></funding-source><award-id>20210204077YY</award-id><principal-award-recipient><name><surname>Zhang</surname><given-names>Yue</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2022</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par106">Hepatocellular carcinoma (HCC) was the sixth most common cancer in the world in 2020 and the third leading cause of cancer death, after lung cancer and colorectal cancer, accounting for 8.3% of all cancer deaths [<xref ref-type="bibr" rid="CR1">1</xref>]. China was the highest incidence rate of HCC. The new cases of HCC in China accounted for 45.3% of the world's total in 2020 [<xref ref-type="bibr" rid="CR1">1</xref>]. The cause of HCC remains unclear, but the main risk factor was chronic hepatitis caused by hepatitis B virus or hepatitis C virus [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. In addition, heavy drinking, aflatoxin contaminated food, and drug toxicity could cause liver cirrhosis, alcoholic liver disease (ALD), non-alcoholic fatty liver disease (NAFLD), metabolic abnormalities (such as type 2 diabetes), and liver fibrosis, all of which may lead to HCC eventually [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR6">6</xref>] (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>A). Primary liver cancer could be divided into HCC, intrahepatic cholangiocarcinoma (ICC), and HCC-ICC mixed type according to pathological and histological sources [<xref ref-type="bibr" rid="CR7">7</xref>]. HCC accounted for 85%-90% of primary HCC [<xref ref-type="bibr" rid="CR4">4</xref>].<fig id="Fig1"><label>Fig. 1</label><caption><p>Trilogy of occurrence and development for HCC and current treatment <bold>A</bold> The cause of HCC is not very clear, but the main risk factor is chronic hepatitis caused by hepatitis B virus or hepatitis C virus. At the same time, due to heavy drinking and drug toxicity, could cause liver cirrhosis, ALD, NAFLD, metabolic abnormalities (such as type 2 diabetes), liver fibrosis and aflatoxin contaminated food, all of the above liver diseases may lead to HCC eventually. <bold>B</bold> Patients with a single or within 3 liver tumors, the tumor diameters less than 3&#x000a0;cm are classified as early cancer (stage I), also known as small HCC, and could be get better prognosis from liver resection, liver transplantation, local ablation, and radiation therapy. Patients with greater tumor, limited to the liver and Child Pugh A/B are considered to have intermediate stage cancer (stage II), which could be benefit from interventional therapy (IT) and chemotherapy. HCC patients with vascular invasion and/or extrahepatic cancer symptoms are considered to have advanced cancer (stage III) which profits by molecular targeted therapy (sorafenib), immune checkpoint inhibitors and TCM treatment based on syndrome differentiation. Patients with end-stage (stage IV) HCC usually show Child Pugh C/D or PS 3&#x02013;4, so they take palliative treatment</p></caption><graphic xlink:href="13020_2022_645_Fig1_HTML" id="MO1"/></fig></p><p id="Par107">The diagnosis of HCC was based on the results of biopsy or imaging combined with molecular marker analysis [<xref ref-type="bibr" rid="CR8">8</xref>]. According to the guidelines for diagnosis and treatment of primary HCC, the stage of HCC was mainly determined by the number and size of liver tumors, vascular invasion, extrahepatic metastasis, Child Pugh grade and performance status (PS) [<xref ref-type="bibr" rid="CR9">9</xref>]. Patients with a single or less than 3 liver tumors and a tumor diameter less than 3&#x000a0;cm were classified as early cancer (stage I), also known as small HCC, and get good prognosis after liver resection, liver transplantation, local ablation, and radiation therapy [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR13">13</xref>]. Patients with greater tumor, limited to the liver and Child Pugh A/B are considered to have intermediate stage cancer (stage II), and benefit from IT and chemotherapy [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. HCC patients with vascular invasion and/or extrahepatic cancer were considered to have advanced cancer (stage III), and benefit from molecular targeted therapy, immune checkpoint inhibitors and TCM treatment based on syndrome differentiation [<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>]. Patients with end-stage (stage IV) HCC usually showed Child Pugh C/D or PS 3&#x02013;4, and thus receive palliative treatment [<xref ref-type="bibr" rid="CR19">19</xref>] (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>B). However, clinically, due to the lack of clear early markers of HCC, most patients were not suitable for surgery and liver transplantation in the middle and late stage of HCC. IT (including radiofrequency ablation, RFA and transcatheter arterial chemoembolization, TACE) was easy to cause local recurrence and post embolism syndrome (PES) [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Immunotherapy and molecularly targeted medications were vulnerable to drug resistance, adverse effects from therapy, and an unsatisfactory objective remission rate of 15% to 20% [<xref ref-type="bibr" rid="CR22">22</xref>&#x02013;<xref ref-type="bibr" rid="CR24">24</xref>]. Given the above-mentioned shortcomings of current clinical treatment approaches, the addition of TCM enhanced the comprehensive anti-tumor effect, and therefore emerges as a focus of HCC treatment [<xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>]. Multiple experiments have investigated the mechanisms of TCM in inhibiting HCC. Alperine inhibited Akt-mediated apoptosis, G2/M cell cycle arrest and the proliferation of hepatoma cells [<xref ref-type="bibr" rid="CR28">28</xref>]. Lappaconitine sulfate induced apoptosis by mediating the mitochondrial apoptosis pathway [<xref ref-type="bibr" rid="CR29">29</xref>]. Bufalin regulated tumor immune microenvironments by Nuclear Factor kappa B (NF-&#x003ba;B) and activates anti-tumor T cell immune response [<xref ref-type="bibr" rid="CR30">30</xref>]. Breviscapine alleviated nonalcoholic steatohepatitis and liver fibrosis by inhibiting TGF-&#x003b2;-activated kinase 1 and toll-like receptor 4 (TLR4) / NF-&#x003ba;B signaling pathway to protect the liver and prevent the further development of liver disease to HCC [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. Astragaloside IV inhibited macrophage M2 polarization, invasion and proliferation of hepatocellular cells by regulating TLR4 / NF-&#x003ba;B / signal transducer and activator of transcription 3 (STAT3) signaling pathway [<xref ref-type="bibr" rid="CR33">33</xref>]. In addition, Astragaloside IV and Curcumin down-regulated the expression of fibroblast growth factor 2, matrix metalloproteinase 2 (MMP2), vascular endothelial growth factor (VEGF), hepatocyte growth factor, and synergistically inhibited nude-mouse model of HCC tumor growth and angiogenesis [<xref ref-type="bibr" rid="CR34">34</xref>]. The above research results demonstrate the huge potential of TCM to combat HCC.</p><p id="Par108">Furthermore, TCM, as an adjuvant therapy, could reduce adverse reactions, increase the curative effect, and prolong the survival time of patients [<xref ref-type="bibr" rid="CR35">35</xref>]. Combination therapy had become a popular strategy for the treatment of HCC. So, this review was divided into two parts. First, the antitumor effect of TCM combined with clinical medication since the establishment of the literature database was summarized. The synergistic effect of TCM combined with surgery, IT, chemotherapy, and targeted drugs in clinical studies were sorted in the second part. It is found that TCM could be used as an adjuvant therapy to intervene in HCC, so as to lay a foundation for the clinical treatment of HCC and the in-depth research of integrated TCM and modern medicine in the treatment of HCC in the future.</p></sec><sec id="Sec2"><title>Methods</title><p id="Par109">This study included basic and clinical studies of TCM combined with arbitrary clinical therapy or drug for HCC published in English as of October 2021 since the establishment of PubMed and Web of Science. We searched 4 sets of keywords in the title and abstract, such as (1) &#x0201c;traditional Chinese medicine&#x0201d; OR &#x0201c;active ingredient&#x0201d; OR &#x0201c;decoction&#x0201d; OR &#x0201c;capsule&#x0201d; OR &#x0201c;injection&#x0201d; OR &#x0201c;formula&#x0201d; OR &#x0201c;granule&#x0201d;; (2) &#x0201c;combine&#x0201d; OR &#x0201c;synergistic&#x0201d; OR &#x0201c;adjuvant treatment&#x0201d;; (3) &#x0201c;prevent&#x0201d; OR &#x0201c;relieve&#x0201d; OR &#x0201c;improve&#x0201d; OR &#x0201c;resistance&#x0201d;; (4) &#x0201c;hepatocellular carcinoma&#x0201d; OR &#x0201c;liver cancer&#x0201d;. Used "AND" combination 4 sets of retrieval results: (1) AND (2) AND (3) AND (4). Search again for the list of references for articles that fulfilled the inclusion criteria after importing the retrieved articles into Endnote X9 to weed out duplicates and filtered them through inclusion and exclusion criteria.</p><sec id="Sec3"><title>Inclusion criteria</title><p id="Par110">The inclusion criteria for these retrieved papers were English publications that have been published or have study findings. The study methods were clinical and basic research. TCM interventions included all extracts and preparations (monomer, active ingredient, compound, capsule, granule, and injection). Combined interventions included commonly used clinical modern medical treatment (chemotherapy, interventional therapy, molecular targeted therapy, and immunotherapy). Clinical research included clinical observation, clinical control study, prospective, and retrospective study. Regardless of age or gender, each subject received a primary liver cancer diagnosis.</p></sec><sec id="Sec4"><title>Exclusion criteria</title><p id="Par111">The language type of the article was not English. Articles on intervention of HCC only with or without TCM were excluded. The disease types of intervention were liver metastasis or other types of tumors. Article types for literature review, meta-analysis and case report were also excluded.</p></sec><sec id="Sec5"><title>Data extraction</title><p id="Par112">Two researchers (LW and ZYW) independently reviewed the retrieved articles, further assessed and extracted data from articles that met the inclusion criteria. Any discrepancies or doubts regarding the data were cleared up through conversation or contact with a third researcher (WXQ).</p><p id="Par113">Basic researches gathered the following information: article title, the type of TCM intervention and detailed information (name, composition or compound ingredients), combination drugs, cellular/animal model, pathway/target and effect.</p><p id="Par114">Clinical researches gathered the following information: article title, the type and detailed information of TCM intervention (name, composition or compound ingredients, dosage), combination drugs/therapy, intervention time (if any), sample size, sample source, primary outcome, secondary outcome and effect. The flow chart of the articles collection is shown in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>.<fig id="Fig2"><label>Fig. 2</label><caption><p>The flow chart of the articles collection This study included basic and clinical studies of TCM combined with arbitrary clinical therapy or drug for HCC published in English as of October 2021 since the establishment of PubMed and Web of Science. The keywords such as "Traditional Chinese medicine", "hepatocellular carcinoma", "combination" and "resistance" were searched to screen articles with inclusion and exclusion criteria. Finally, 65 basic research articles and 16 clinical articles were collected</p></caption><graphic xlink:href="13020_2022_645_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec6"><title>Current situation of therapeutic drugs for HCC</title><p id="Par115">In the basic study of clinical drugs for the treatment of HCC, it was found that mitomycin C (MMC), doxorubicin (DOX), cyclophosphamide (CTX) and 5-fluorouracil (5-FU) affect the development of tumor by interfering with DNA synthesis [<xref ref-type="bibr" rid="CR36">36</xref>&#x02013;<xref ref-type="bibr" rid="CR39">39</xref>]. However, with the use of drugs, it was found that DOX and 5-FU were prone to severe cardiotoxicity, and the cytotoxicity caused by CTX usually leads to bone marrow suppression and immunosuppression [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR40">40</xref>&#x02013;<xref ref-type="bibr" rid="CR42">42</xref>]. Platinum chemotherapeutic drugs interfered with DNA repair mechanism, led to DNA damage, and then induced cancer cell apoptosis [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. Sorafenib was an oral multi-kinase inhibitor, targeting VEGF receptor, RAF and PDGF receptor, which had anti-angiogenesis and direct anti-tumor effects [<xref ref-type="bibr" rid="CR45">45</xref>]. Platinum chemotherapy drugs and sorafenib were prone to drug resistance, and there were serious adverse reactions after long-term use [<xref ref-type="bibr" rid="CR46">46</xref>&#x02013;<xref ref-type="bibr" rid="CR48">48</xref>]. ICIs such as anti-programmed cell death protein 1 (PD1) antibody and its ligand (PD-L1) are a new method for clinical treatment of HCC [<xref ref-type="bibr" rid="CR49">49</xref>]. However, immune related adverse events (irAEs) had become a difficult problem in clinical practice, the main clinical manifestations are skin toxicity, liver toxicity and gastrointestinal toxicity [<xref ref-type="bibr" rid="CR50">50</xref>]. In the face of the above-mentioned clinical side effects of chemotherapeutic drugs commonly used in HCC and the characteristics of drug resistance, the treatment of HCC is very passive. Fortunately, TCM played a corresponding role in the gastrointestinal reactions and toxic side effects caused by chemotherapy. Therefore, it seems that the intervention of TCM could achieve a more optimized treatment outcome.</p></sec><sec id="Sec7"><title>Combination of TCM and MMC</title><p id="Par116">Hau DouMong et al. found that Shih Chuan-Ta-Pu-Tang (SCTPT) or Shi-Hung-One (SHO) combined with MMC could prolong the survival time of tumor-bearing mice [<xref ref-type="bibr" rid="CR51">51</xref>]. The combination of polyporus umbellatus extract and MMC improved the life span of S180-tumor bearing mice, changed the tumor micro-environment, increased lymphocyte infiltration, induced cancer cell atrophy and fibrosis by inhibiting the synthesis of DNA, RNA and protein [<xref ref-type="bibr" rid="CR52">52</xref>]. Xuefu Zhuyu tang combined with MMC could specifically inhibit the survival rate of tumor cells and prolong the average survival time of tumor-bearing mice [<xref ref-type="bibr" rid="CR53">53</xref>]. Early studies on MMC found that combining it with herbal extract or a Chinese medicine ingredient improved its therapeutic effects and lengthened the lives of tumor-bearing mice by boosting their immune systems. (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1).</p></sec><sec id="Sec8"><title>Combination of TCM and CTX</title><p id="Par117">The research found that neutral polysaccharide from Panax notoginseng (NPPN) alleviated the bone marrow suppression caused by CTX treatment, inhibited the growth of tumor in mice bearing H22 tumor, improved the antitumor effect of CTX and alleviated adverse reaction [<xref ref-type="bibr" rid="CR54">54</xref>]. TCM classic prescription Shenling Baizhu Powder combined with CTX could reduce the expression of NF-&#x003ba;B, B-cell lymphoma-2 (Bcl-2)/B-cell lymphoma-extra large (Bcl-xl), survivin and X-linked inhibitor of apoptosis (XIAP) in tumor tissues in mice, which promoted the activation of caspase-3/9, so as to inhibit tumor growth [<xref ref-type="bibr" rid="CR55">55</xref>]. Shengbai Decoction reduced the content of inflammatory factors in the serum of mice after CTX and was found to promote the apoptosis of HCC cells through p53 pathway, and reduce side effects and prolong survival [<xref ref-type="bibr" rid="CR56">56</xref>]. It was found that He-Wei Granule combined with CTX reduced the hepatotoxicity and bone marrow inhibition caused by CTX, increased cleaved caspase-3 to promote apoptosis and inhibit autophagy [<xref ref-type="bibr" rid="CR57">57</xref>]. The studies above showed that TCM could enhance CTX, promote the apoptosis of hepatoma cells. The combination improved the antitumor effect, reduced the toxic and side effects of CTX, and finally improved the survival time of tumor-bearing mice (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1).</p></sec><sec id="Sec9"><title>Combination of TCM and DOX</title><p id="Par118">Both icaritin and ginger extract promoted DOX and induced apoptosis of hepatoma cells. And ginger extract reduced malondialdehyde and tumor necrosis factor (TNF)-&#x003b1; to improve the cardiotoxicity caused by DOX [<xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR59">59</xref>]. Dihydroartemisinin, Y<sub>6</sub> (epigallocatechin gallate derivative) and astragalus polysaccharides overcame the drug resistance of DOX and restored its sensitivity in the treatment of HCC, while astragalus polysaccharides could regulate the expression level of serum cytokines in mice bearing H22 tumor and inhibit tumor progression [<xref ref-type="bibr" rid="CR60">60</xref>&#x02013;<xref ref-type="bibr" rid="CR62">62</xref>]. Rosmarinic acid, cinobufacini and quercetin separately synergized DOX to induce the apoptosis of hepatoma cells and boost the therapeutic effect of DOX [<xref ref-type="bibr" rid="CR63">63</xref>&#x02013;<xref ref-type="bibr" rid="CR65">65</xref>]. Dahuang Zhechong Pill (DHZCP) is a classic TCM prescription, which mediated the multidrug resistance (MDR) of HCC and reduced the outflow of drugs by improving the activity level of adenosine triphosphate (ATP) in SMMC-7721 cells, and thereby enhanced the effect of DOX [<xref ref-type="bibr" rid="CR66">66</xref>]. Meanwhile, DHZCP inhibited angiogenesis, promoted apoptosis and reversed resistance on DOX-resistant SMMC-7721 xenografts in mice [<xref ref-type="bibr" rid="CR67">67</xref>]. The active ingredient of Tanshinone IIA could prolong the survival time of tumor-bearing mice, reduce the expression of cytochrome P450, cytochrome P450 Family 3 Subfamily A Member 4 (CYP3A4) and pregnane X receptor (PXR), and reduce the toxicity of DOX and the level of serum aspartate transaminase (AST) [<xref ref-type="bibr" rid="CR68">68</xref>]. Tanshinone IIA could also improve the tumor micro-environment by reducing tumor hypoxia and regulating the expression of &#x003b1;-Smooth muscle actin(&#x003b1;-SMA) and collagen IV to remodel the tumor vasculature and inhibit angiogenesis after combined treatment [<xref ref-type="bibr" rid="CR69">69</xref>]. These studies showed that TCM could alleviate the cardiotoxicity of DOX. The combination further inhibited tumor formation in tumor-bearing mice by promoting apoptosis and inhibiting the proliferation of HCC cells and improved the sensitivity of DOX in the treatment of HCC (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1).</p></sec><sec id="Sec10"><title>Combination of TCM and DDP</title><p id="Par119">When falcarindiol or astragaloside IV was combined with DDP separately, the sensitivity of tumor-bearing mice to DDP and the antitumor effect of DDP by inducing apoptosis of HCC cells could be enhanced [<xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR71">71</xref>]. It was found that matrine could reduce the toxicity of DDP, induce apoptosis of hepatoma cells in tumor-bearing mice through reducing the expression of survivin [<xref ref-type="bibr" rid="CR72">72</xref>]. Bushen Huayu Jiedu recipe combined with DDP was administered to H22 tumor-bearing mice, the high-dose group showed obvious repression rate on the mean weight of tumor, which was better than that of DDP alone (77.69% vs 68.46%) [<xref ref-type="bibr" rid="CR73">73</xref>]. In clinic, two or more chemotherapeutic drugs are often used in refractory HCC to improve sensitivity, which, however, also brings increased toxicity [<xref ref-type="bibr" rid="CR39">39</xref>]. Researchers found that wheat germ extract could inhibit the proliferation of a variety of HCC cells, induce the expression of poly ADP-ribose polymerase (PARP) in Hep3B cells, cause apoptosis, and enhance the inhibitory effect of DDP and 5-FU on HCC cells [<xref ref-type="bibr" rid="CR74">74</xref>]. Solanum nigrum, a TCM with antipyretic and analgesic effects, is a commonly used antitumor drug [<xref ref-type="bibr" rid="CR75">75</xref>]. Wang Chienkai et al. found that aqueous extract of <italic>Solanum nigrum</italic> (AE-SN) could promote the apoptosis of Hep3B and HepJ5 by inducing cleaved caspase-7, activating intracellular autophagy, and enhancing the cytotoxicity of DDP and DOX to hepatoma cell lines [<xref ref-type="bibr" rid="CR76">76</xref>]. L-OHP, as one of the third generation of platinum drugs, do not produce cross resistance to DDP [<xref ref-type="bibr" rid="CR77">77</xref>]. Researchers found that the purified polysaccharide extracted and isolated from the fruit bodies of <italic>L. edodes</italic> combined with L-OHP induced apoptosis and inhibited the activity of cancer cells, inhibited the angiogenesis and reduced the adverse reactions such as diarrhea and liver injury in tumor-bearing mice [<xref ref-type="bibr" rid="CR78">78</xref>]. The hepatoma cells treated with L-OHP alone did not significantly induce apoptosis, accompanied with high expression of Yes associated protein (YAP) [<xref ref-type="bibr" rid="CR79">79</xref>]. However, its combination with Huaier induced the apoptosis of hepatoma cells [<xref ref-type="bibr" rid="CR79">79</xref>]. It has been found that demethylcantharidin precluded the repair of cisplatin-induced DNA cross-links by inhibiting protein phosphatase 2A (PP2A) to avoid the resistance to cisplatin in mice with hepatoma [<xref ref-type="bibr" rid="CR80">80</xref>]. The administration sequence of demethylcantharidin in advance of cisplatin had a lower combination index than that of cisplatin in advance of demethylcantharidin in SK-Hep-1 cells (0.72&#x02009;&#x000b1;&#x02009;0.07 vs 0.99&#x02009;&#x000b1;&#x02009;0.08), which produced a significant synergistic effect in vitro [<xref ref-type="bibr" rid="CR80">80</xref>]. Therefore, experimental studies showed that TCM promoted the apoptosis of hepatoma cells treated with platinum drugs, overcame the MDR, and improved the nephrotoxicity and gastrointestinal side effects of platinum drugs on tumor-bearing mice (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1).</p></sec><sec id="Sec11"><title>Combination of TCM and 5-FU</title><p id="Par120">ZYGII (a kind of triterpenoid saponins isolated from <italic>Sanguisorba officinalis L</italic>), pleurospermum lindleyanum extract and furanodiene (a sesquiter mec pene component in zedoary turmeric rhizome) could regulate the cell cycle process, induce apoptosis and promote the anticancer effect of 5-FU in hepatoma cells [<xref ref-type="bibr" rid="CR81">81</xref>&#x02013;<xref ref-type="bibr" rid="CR84">84</xref>]. Furadiene resisted angiogenesis and induced the production of reactive oxygen species (ROS) [<xref ref-type="bibr" rid="CR83">83</xref>, <xref ref-type="bibr" rid="CR84">84</xref>]. Ciji-Hua&#x02019;ai-Baosheng II Formula could improve the anorexia and gastrointestinal injury caused by chemotherapy in tumor-bearing mice by affecting the appetite regulatory factors in the hypothalamic central nervous system and feeding area, and enhance the antitumor effect of 5-FU [<xref ref-type="bibr" rid="CR85">85</xref>]. Curcumin is an anticancer component of turmeric. It could inhibit the proliferation of HCC cells and improve the sensitivity of 5-FU chemotherapy by increasing the intestinal microbiota of mice when combined with 5-FU [<xref ref-type="bibr" rid="CR86">86</xref>]. The total water-soluble flavonoids isolated from <italic>Isodon lophanthoides var. gerardianus (Benth.) H. Hara</italic> combined with 5-FU to inhibit tumor activity by promoting apoptosis and improving ROS level [<xref ref-type="bibr" rid="CR87">87</xref>]. Li Fengli et al. found that H1 (a derivative of tetrandrine) could increase the cytotoxicity of 5-FU in BEL7402/5-FU cells by blocking STAT3/myeloid cell leukemia-1 (Mcl-1) pathway and inducing p53 up-regulated modulator of apoptosis (PUMA), reverse the resistance to 5-FU and further promote apoptosis of drug-resistant cells [<xref ref-type="bibr" rid="CR88">88</xref>]. Huaier inhibited the proliferation of HuH28 by down regulating STAT3 as well as its downstream genes, and had stronger effects in cell cycle arrest, induced-apoptosis and anti-metastasis when combined with 5-FU [<xref ref-type="bibr" rid="CR89">89</xref>]. The combination of puerarin, or luteolin, or resveratrol with 5-FU enhanced the apoptosis of hepatoma cells, which might be related to the decreased activity of dihydropyrimidine dehydrogenase (DPD) in 5-FU metabolism [<xref ref-type="bibr" rid="CR90">90</xref>&#x02013;<xref ref-type="bibr" rid="CR93">93</xref>]. Therefore, TCM combined with 5-FU could cause cell cycle arrest, promote apoptosis, enhance oxidative stress, and prevent the continuous proliferation of HCC cells. Additionally, TCM reduced the adverse reactions such as anorexia caused by 5-FU (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1).</p></sec><sec id="Sec12"><title>Combination of TCM and sorafenib</title><p id="Par121">It was found that both Bushen Jianpi Formula and cucurbitacin B induced apoptosis of HCC cells by regulating the levels of caspase-3 and caspase-9, and inhibited the proliferation of tumor cells in vivo in combination with sorafenib [<xref ref-type="bibr" rid="CR94">94</xref>, <xref ref-type="bibr" rid="CR95">95</xref>]. Bufalin or Celastrol (major active ingredient of Tripterygium wilfordii) combined with sorafenib reduced the secretion of VEGF, inhibited tumor angiogenesis in mice bearing tumor and enhanced the activity of sorafenib [<xref ref-type="bibr" rid="CR96">96</xref>&#x02013;<xref ref-type="bibr" rid="CR99">99</xref>]. Curcumin and Oridonin (the core bioactive component of rabdosia rubescens) could block the epithelial&#x02013;mesenchymal transition (EMT) and overcome the limitations of sorafenib [<xref ref-type="bibr" rid="CR100">100</xref>, <xref ref-type="bibr" rid="CR101">101</xref>]. Magnolol (a bioactive compound extracted from the bark of the Magnolia officinalis) and LicA (Licochalcone A, the main component of Licorice) enhanced the inhibition of the invasion of HCC cells by sorafenib in vivo and in vitro [<xref ref-type="bibr" rid="CR102">102</xref>, <xref ref-type="bibr" rid="CR103">103</xref>]. Besides, LicA was found to reduce the incidence of lung metastasis in tumor-bearing mice [<xref ref-type="bibr" rid="CR103">103</xref>]. Compound kushen injection (CKI, also known as Yan shu injection), an anticancer Chinese patent medicine, activated immunosuppression, reshapes the immune microenvironment of HCC and enhanced the antitumor activity of sorafenib [<xref ref-type="bibr" rid="CR104">104</xref>]. Berbamine (a natural bisbenzylisoquinoline alkaloid isolated from Berberis amurensis) or ouabain cooperated with sorafenib to reduce the expression of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor (IGF1R) and to inhibit the growth of hepatoma cells by inhibiting sarcoma gene (Src). Berbamine also improved the sensitivity of sorafenib resistant to HepG2-SR cells [<xref ref-type="bibr" rid="CR105">105</xref>]. Hydroxygenkwanin (HGK), a natural herbal extract from Daphne genkwa, inhibited the activity of class I histone deacetylase (HDAC), which could improve the therapeutic effect after combined with anti-cancer drugs such as sorafenib [<xref ref-type="bibr" rid="CR106">106</xref>]. Artesunate (artemisinin derivative extracted from Artemisia annua) significantly enhanced the anticancer effect of sorafenib on HCC cell lines in vitro and mice bearing Huh7 tumor, which was attributed to the synergistic effect of lysosomal activation induced by oxidation, induced ferroptosis and improved the sensitivity of sorafenib to HCC cells [<xref ref-type="bibr" rid="CR107">107</xref>]. In conclusion, TCM combined with sorafenib inhibited the proliferation and invasion of HCC cells through inducing apoptosis and blocking the EMT, and improved the sensitivity of sorafenib to HCC cells (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1).</p><p id="Par122">In addition, the combination of TCM with ICIs, other chemotherapeutic drugs and molecular targeted drugs improved the antitumor effect of the drugs [<xref ref-type="bibr" rid="CR108">108</xref>&#x02013;<xref ref-type="bibr" rid="CR113">113</xref>] (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1).</p></sec><sec id="Sec13"><title>TCM overcomes MDR</title><p id="Par123">With the increase of treatment cycle, the drug resistance of HCC to cytotoxicity affects the effect of chemotherapy, and the main mechanism is MDR [<xref ref-type="bibr" rid="CR114">114</xref>]. As an adjuvant drug after chemotherapy, TCM could prolong the survival time of cancer patients, which might be related to its obstruction of MDR related pathways [<xref ref-type="bibr" rid="CR115">115</xref>]. Cantharidin inhibited the MDR1 gene, blocked the P-gp pathway, and reversed MDR [<xref ref-type="bibr" rid="CR116">116</xref>]. Gambogenic acid, an extract of Gamboge, could mediate NF-&#x003ba;B and MAPK pathway through P-gp, promote cell apoptosis, block MDR and improve the sensitivity of hepatoma cells resistant to DOX and paclitaxel [<xref ref-type="bibr" rid="CR117">117</xref>]. Another natural compound Asiatic acid Naringenin (AANG) targeted the tumor micro-environment, inhibited transforming growth factor-&#x003b2;1 (TGF-&#x003b2;1)/Smad signaling, and reduced the MDR caused by P-gp [<xref ref-type="bibr" rid="CR118">118</xref>]. Apigenin, a natural flavonoid, reduced inflammation and oxidation, down-regulated the expression of HIF-1&#x003b1; through the inhibition of protein kinases B (PKB, also known as Akt)/p-Akt pathway and Hsp90, and overcame the drug resistance of paclitaxel induced by hypoxia [<xref ref-type="bibr" rid="CR119">119</xref>]. Chinese herbal extract platycodin D reversed the resistance of HCC cells to chemotherapeutic drugs through ERK1/2 pathway [<xref ref-type="bibr" rid="CR120">120</xref>]. In conclusion, the extracts from the above herbs could block the occurrence of MDR, HIF-1, P-gp and inflammation related pathway (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2).</p></sec><sec id="Sec14"><title>Clinical study of TCM combined with modern medicine in the treatment of HCC</title><p id="Par124">Hepatectomy and liver transplantation are good choices in the early stage of HCC, but they are only applicable for a few patients and with a high risk of postoperative recurrence [<xref ref-type="bibr" rid="CR121">121</xref>]. IT is beneficial for patients with middle-term HCC, but prone to local complications and post embolization syndrome (PES) [<xref ref-type="bibr" rid="CR21">21</xref>]. Advanced HCC is usually treated with routine treatment or symptomatic treatment in order to prolong the survival time of patients [<xref ref-type="bibr" rid="CR122">122</xref>]. In light of the current situation of clinical treatment of HCC, TCM adjuvant treatment seems to show better outcome indicators.</p></sec><sec id="Sec15"><title>TCM combined with Surgery for HCC</title><p id="Par125">In a RCT after an operation of 364 patients with small HCC from 5 centers, cinobufagin and Jiedu Granule (THM group) showed great advantages in prolonging the recurrence time and improving the survival rate over TACE. The median recurrence-free survival (RFS) was 46.9 vs 34.4&#x000a0;months (<italic>P</italic>&#x02009;=&#x02009;0.048), Cox proportional hazard regression analysis showed that THM (hazard ratio [HR]&#x02009;=&#x02009;0.57,95% confidence interval [CI], 0.37&#x02013;0.86) was an independent protection factor affecting overall survival (OS). The rate of 5-years OS was 71.11% vs 63.04%, respectively [<xref ref-type="bibr" rid="CR123">123</xref>]. In another phase IV study of 1044 patients after HCC surgery from 39 centers, the mean RFS was 75.5 vs 68.5&#x000a0;weeks (HR 0.67, 95% CI, 0.55&#x02013;0.81), and the 2-years OS rate was 95.19% vs 91.46% (HR&#x02009;=&#x02009;0.553, 95% CI, 0.33&#x02013;0.92) in the Huaier group treated with Huaier Granule and in the control group. In addition, Huaier Granule treatment significantly reduced the recurrence and metastasis rate of HCC in patients without HBV infection [<xref ref-type="bibr" rid="CR124">124</xref>]. In a retrospective study of 137 patients after HCC surgery, it was found that the recurrence rate of HCC treated with Erzhu Qinggan Jiedu recipe (ESQJR) combined with modern medicine was reduced by 22.6% (57.4% vs 34.8%, <italic>P</italic>&#x02009;=&#x02009;0.008), and the average OS was significantly longer than that of modern medicine alone (139.9 vs 97.2&#x000a0;months, <italic>P</italic>&#x02009;=&#x02009;0.043) [<xref ref-type="bibr" rid="CR125">125</xref>]. A clinical study of 120 cases found that Jianpi Huayu therapy prolonged the median OS (52.6 vs 49.8&#x000a0;months, <italic>P</italic>&#x02009;=&#x02009;0.048) and median disease-free survival (28.7 vs 22.6&#x000a0;months, <italic>P</italic>&#x02009;=&#x02009;0.045) of postoperative HCC patients compared with the control group, and the recurrence rate was significantly lower than that of the control group (80% vs 93.9%) [<xref ref-type="bibr" rid="CR126">126</xref>]. These studies proved the effectiveness of TCM on postoperative intervention of HCC, delayed the progress of the disease, and significant improvement of the survival time of postoperative patients (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S3).</p></sec><sec id="Sec16"><title>TCM combined with IT for HCC</title><p id="Par126">The combination of Jianpi Ligan Decoction (JLD) and TACE (n&#x02009;=&#x02009;103) or RFA (n&#x02009;=&#x02009;95) reduced the adverse effects and improved the success rate of treatment, and the 3-year OS rate was improved compared with only TACE (37.74% vs 26.00%, HR&#x02009;=&#x02009;0.62, 95% CI, 0.38&#x02013;0.99) or only RFA (38.30% vs 27.08%, HR&#x02009;=&#x02009;1.78, 95% CI, 1.08&#x02013;2.93) [<xref ref-type="bibr" rid="CR127">127</xref>, <xref ref-type="bibr" rid="CR128">128</xref>]. In the cohort study of 340 HCC patients, compared with the thermal ablation (RFA or microwave ablation [MWA]) group, the Huaier Granule combined with thermal ablation showed an increase in both the median OS (35 vs 31&#x000a0;months, HR&#x02009;=&#x02009;0.76, 95%CI, 0.54&#x02013;1.07) and median progression-free survival (PFS) (24 vs 12.5&#x000a0;months, HR&#x02009;=&#x02009;0.67, 95%CI, 0.48&#x02013;0.94), and a significant decrease in the rate of extrahepatic metastasis, which could alleviate the side effects of patients to some extent [<xref ref-type="bibr" rid="CR129">129</xref>]. The study found that the rate of 3-year OS of the Chaihu-Huaji Decoction combined with the TACE group was significantly higher than that of the control group (26.47% vs 13.06%, HR&#x02009;=&#x02009;1.61, 95%CI, 1.02&#x02013;2.53), without hepatorenal toxicity [<xref ref-type="bibr" rid="CR130">130</xref>]. After cantharidin capsule was administered with TACE, the overall effective rate increased (40.6% vs 36.8%, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), with an improved Karnofsky performance status (KPS), a reduced alpha fetoprotein (AFP) value, a reduced gastrointestinal reaction and an improved quality of life of patients compared with the control group [<xref ref-type="bibr" rid="CR131">131</xref>]. After a long-term follow-up of 399 patients, Compound Ruanjian Hugan tablet (RJH) was found to play a positive role in the treatment of small HCC. The median OS of RJH combined with the IT group was better than the IT group and simple operation group (151.20, 43.8 vs 20.77&#x000a0;months). The combined group compared with the IT group, the 10-year OS rate was 57.10% and 33.34% [<xref ref-type="bibr" rid="CR132">132</xref>]. In a prospective study of Ginsenoside Rg3 was combined with TACE in 228 HCC patients, compared with the control group, the median OS was 13.2 vs 10.1&#x000a0;months (HR&#x02009;=&#x02009;0.63, 95% CI, 0.46, 0.85) and a higher disease control rate of 69.7% vs 51.3%(<italic>P</italic>&#x02009;=&#x02009;0.012) was achieved [<xref ref-type="bibr" rid="CR133">133</xref>]. In a RCT of 98 HCC cases, Jinlong Capsule combined with TACE had a much higher overall remission rate (60.38% vs 40%, <italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05), and a decreased KPS and levels of serum osteopontin (OPN) compared with TACE alone. The combination also inhibited the progress of the disease and improved the prognosis [<xref ref-type="bibr" rid="CR134">134</xref>]. In a study with a follow-up for 86&#x000a0;months with 266 HCC patients, Jiedu Granule (JD) combined with TACE prolonged time to progress (TTP) (8.67 vs 5.37 vs 4.57&#x000a0;months) and the median OS (21.43 vs 23.23 vs 13.97&#x000a0;months) compared with TACE alone and TACE plus sorafenib [<xref ref-type="bibr" rid="CR135">135</xref>] (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S4). It followed that the combination of TCM prolonged the PFS and OS, increased the effective rate of IT and improved the adverse reactions of patients with HCC.</p></sec><sec id="Sec17"><title>TCM combined with CT for HCC</title><p id="Par127">Phase II study found that YIV-906 combined with capecitabine (an oral 5-FU prodrug [<xref ref-type="bibr" rid="CR136">136</xref>]) had the median OS of 6&#x000a0;months in patients with 39 HCC and showed better clinical effects on patients with low initial AFP value, those uninfected by HBV and those previously untreated [<xref ref-type="bibr" rid="CR137">137</xref>]. A retrospective cohort study involving 328 cases found that TCM combined with conventional therapies (include TACE, ablation, target therapy, or chemotherapy) was superior to TCM alone or CT alone, with the median OS of 11 vs 8.6 vs 9.4&#x000a0;months(<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01). Multivariate analysis showed that integrative therapy belonged to the protective factor and had a lower risk of death in contrast to the CT group (HR&#x02009;=&#x02009;0.59, 95% CI 0.42&#x02013;0.84) or CHM group (HR&#x02009;=&#x02009;0.59; 95% CI, 0.46&#x02013;0.77). Under integrative therapy, Child Pugh class A and better PS could benefit from OS, which suggested that patients with HCC benefited from early TCM medicine intervention [<xref ref-type="bibr" rid="CR138">138</xref>]. Liao Yueh-Hsiang et al. conducted a retrospective study on 127,237 HCC cases in Taiwan Health Insurance Research Database and found that Jiawei Xiaoyao san (HR&#x02009;=&#x02009;0.89, 95% CI, 0.81&#x02013;0.96) and Chaihu Shugan Decoction (HR&#x02009;=&#x02009;0.86, 95% CI&#x02009;=&#x02009;0.78&#x02013;0.95) were effective TCM preparations in improving the survival rate of patients with HCC, and the mean follow-up period was 5.67 vs 5.49&#x000a0;years for TCM and non-TCM users, respectively. Compared with non-TCM users, TCM reduced the risk of death (HR&#x02009;=&#x02009;0.65, 95% CI, 0.64&#x02013;0.66)<italic>.</italic> Meanwhile, TCMs were found to have significant protective effects in different subgroups of patients with chronic liver diseases [<xref ref-type="bibr" rid="CR139">139</xref>] (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S5).</p><p id="Par128">We gathered and compiled the median OS data from the clinical data of integrated traditional Chinese and modern medicine in the treatment of advanced HCC [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR129">129</xref>, <xref ref-type="bibr" rid="CR133">133</xref>, <xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR137">137</xref>, <xref ref-type="bibr" rid="CR138">138</xref>]. Taking the use of TCM as an exposure factor, they were divided into the TCM group, the Convention group (modern medicine treatment only), and the Integration group (including TCM combined with interventional or chemotherapy drugs), and the data of the three groups were simply compared. As shown in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>, the median OS of the Integration group was higher than that of the Convention group and the TCM group, which was 16.71 vs 15.11 vs 7.72&#x000a0;months (<italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05). We found that the combination of TCM and modern medicine in the treatment of HCC seemed to prolong the median OS of samples. However, because of the sparse data and wide variations in treatment duration and research design across clinical studies, our results have no statistical differences, which could not more objectively explain the advantages of integrated traditional Chinese and Modern medicine in the treatment of HCC. More sample sizes and studies will be needed in the future to verify this conclusion. For a list of the ingredients in each TCM compound prescription, see Table S6 in Additional File <xref rid="MOESM1" ref-type="media">1</xref>.<fig id="Fig3"><label>Fig. 3</label><caption><p>The median OS data for advanced HCC Gathered and compiled the median OS data from the clinical data of integrated traditional Chinese and modern medicine in the treatment of advanced HCC. The median OS of the Integration group was higher than that of the Convention group and the TCM group, which was 16.71 vs 15.11 vs 7.72&#x000a0;months (<italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05)</p></caption><graphic xlink:href="13020_2022_645_Fig3_HTML" id="MO3"/></fig></p></sec></sec><sec id="Sec18"><title>Discussion</title><p id="Par129">HCC is one of the intractable malignant tumors with rapid progression and short survival [<xref ref-type="bibr" rid="CR1">1</xref>]. Most patients lose the chance of radical cure when diagnosed with HCC. The tumor in them cannot be removed and is prone to recurrence and metastasis, and only be treated with chemotherapy, targeted drugs and ICIs. Their median survival time is only 3 to 7&#x000a0;months [<xref ref-type="bibr" rid="CR140">140</xref>]. The survival time of patients with advanced HCC can no longer be effectively improved. Furthermore, liver dysfunction and adverse reactions after treatment also limit the follow-up treatment of HCC [<xref ref-type="bibr" rid="CR141">141</xref>]. Therefore, patients with HCC have many problems, such as short survival time, poor prognosis, the lack of mild and effective treatment and so on. Previous studies have found that the comprehensive treatment with TCM was effective for patients in the middle and advanced stages of HCC, which extended PFS to some extent, improved patients' quality of life and long-term OS by improving myelosuppression caused by chemotherapy, and gastrointestinal side effects, while it had a safety profile [<xref ref-type="bibr" rid="CR142">142</xref>]. In the process of treating HCC with TCM, the anti-cancer ability of patients was improved [<xref ref-type="bibr" rid="CR143">143</xref>]. Although TCM has a poorer role in killing hepatoma cells than chemotherapy and targeting drugs, the combination of TCM and modern medicine provides a direction for future clinical research.</p><p id="Par130">This review systematically summarized the effect of TCM combined with clinical drugs and modern medicine therapy on the treatment of HCC. The basic researches included TCM combined with chemotherapy drugs, molecular targeted drugs and ICIs. This study found that integrated traditional Chinese and modern medicine inhibited MDR pathway by reversing P-gp. And through the EGFR and VEGF pathway inhibited the cell proliferation, tumor micro-vessel production and metastasis of HCC, regulated autophagy and induced apoptosis of hepatoma cells. TCM increased ROS production and induced ferroptosis in HCC cells. TCM promoted the curative effect of PD-1 or PD-L1, so as to enhance the immunity of tumor-bearing mice, improve the tumor micro-environment, realize the anti-tumor and improve drug resistance by enhancing chemotherapy, molecular targeted drugs and ICIs (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>).<fig id="Fig4"><label>Fig. 4</label><caption><p>Related pathways and mechanisms involved in the treatment of HCC Integrated traditional Chinese and modern medicine inhibits MDR pathway by reversing P-gp. And through the EGFR and VEGF pathway inhibit the cell proliferation, tumor micro-vessel production and metastasis of HCC, regulate autophagy and induce apoptosis of hepatoma cells. TCM increases ROS production and induces ferroptosis in HCC cells. TCM promotes the curative effect of PD-1 or PD-L1, so as to enhance the immunity of tumor-bearing mice, improve the tumor micro-environment, realize the anti-tumor and improve drug resistance by enhancing chemotherapy, molecular targeted drugs and ICIs</p></caption><graphic xlink:href="13020_2022_645_Fig4_HTML" id="MO4"/></fig></p><p id="Par131">In addition to summarizing the main effective mechanisms of TCM combined treatment for HCC, this review also evaluated the role of TCM in clinical researches. In HCC (early) surgery, TCM prolonged the median RFS of patients, reduced the recurrence rate after surgery, prolonged the OS [<xref ref-type="bibr" rid="CR123">123</xref>&#x02013;<xref ref-type="bibr" rid="CR126">126</xref>]. In advanced HCC, TCM reduced gastrointestinal adverse reactions of other therapies, thereby improving the quality of life of patients [<xref ref-type="bibr" rid="CR127">127</xref>&#x02013;<xref ref-type="bibr" rid="CR129">129</xref>]. TCM and IT had good synergistic effect, and improve the total effective rate, delay the progress of the disease [<xref ref-type="bibr" rid="CR129">129</xref>, <xref ref-type="bibr" rid="CR131">131</xref>, <xref ref-type="bibr" rid="CR134">134</xref>]. But in this study, we found that integrated traditional Chinese and modern medical treatment of HCC did not form a systematic treatment system and the treatment principles were not really clear. Currently, symptomatic care makes up the majority of combined TCM and modern medicine treatment for HCC. If it can provide a relatively fixed, mild and effective TCM compound or proprietary Chinese medicine in each stage of HCC or in combination with various chemotherapy drugs, interventional therapy and immunotherapy, it will be more conducive to the treatment of clinicians and the survival of patients. Due to the HCC's complicated etiology, quick advancement, and patients' varied health statuses, there are frequently a lot of ambiguities in clinical therapy, which lead to a poor clinical therapeutic outcome when compares to the RCT research. Based on these problems, maybe real-world study could help understand the safety and effectiveness of integrated treatment of HCC, to obtain the evidence-based medicine evidence of TCM and provide a novel HCC treatment plan [<xref ref-type="bibr" rid="CR144">144</xref>, <xref ref-type="bibr" rid="CR145">145</xref>].</p><p id="Par132">This review introduced the molecular mechanism and clinical efficacy of TCM in the treatment of HCC and found that TCM played a positive role in the treatment of HCC in each stage and delayed the recurrence and metastasis of HCC, which laid a foundation for the further research and clinical use of HCC. But the deficiencies of the research were found. First off, this study did not examine the effectiveness or mechanism of action of TCM alone in the development of HCC; it only covered the combination therapy of TCM and contemporary medicine. Because TCM combined with modern medicine is a common choice for the treatment of advanced HCC. Secondly, only a small number of clinical studies (especially RCT) of TCM combined with modern medicine were reviewed, and most of them are retrospective studies, which might be related to the poor prognosis and short survival time of patients with HCC. Therefore, clinical researchers need to carry out multi-center clinical studies with a large sample size on patients with HCC and provide evidence-based medical evidence of TCM in the treatment of HCC. In addition, there were few studies on the combination of TCM and emerging therapy ICIs in the treatment of HCC. Previous studies have found that TCM improves the immune function of patients, which also points out a direction for further research.</p></sec><sec id="Sec19"><title>Conclusion</title><p id="Par133">In summary, this review summarized experimental and clinical studies of TCM combined with modern medicine for the treatment of HCC, and TCM was found to synergize with modern medicine to inhibit the development of HCC, enhance sensitivity after chemotherapeutic resistance, improve adverse effects produced by chemotherapeutic agents and molecular targeted drugs, and prolong survival after surgery or interventional therapy. To some extent, it alleviates recurrence and metastasis of HCC and plays a role of attenuating cancer, which suggest that TCM treatment can serve as an adjuvant therapy to intervene the treatment of HCC. The paper provides a reference for the treatment and research of HCC in the future.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Information</title><sec id="Sec20"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="13020_2022_645_MOESM1_ESM.xlsx"><caption><p><bold>Additional file 1: Table S1.</bold> Basic research on TCM combined with modern medical drugs in the treatment of HCC. <bold>Table S2.</bold> TCM overcome MDR. <bold>Table S3. </bold>TCM combine with Surgery for HCC. <bold>Table S4. </bold>TCM combined with IT for HCC. <bold>Table S5.</bold> TCM combined with CT for HCC. S6<bold>. Table S6.</bold> The components of TCM Formulas mentioned in this review.</p></caption></media></supplementary-material></p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>TCM</term><def><p id="Par2">Traditional Chinese medicine</p></def></def-item><def-item><term>HCC</term><def><p id="Par3">Hepatocellular carcinoma</p></def></def-item><def-item><term>IT</term><def><p id="Par4">Interventional therapy</p></def></def-item><def-item><term>CT</term><def><p id="Par5">Conventional therapy</p></def></def-item><def-item><term>ALD</term><def><p id="Par6">Alcoholic liver disease</p></def></def-item><def-item><term>NAFLD</term><def><p id="Par7">Non-alcoholic fatty liver disease</p></def></def-item><def-item><term>ICC</term><def><p id="Par8">Intrahepatic cholangiocarcinoma</p></def></def-item><def-item><term>PS</term><def><p id="Par9">Performance status</p></def></def-item><def-item><term>VEGF</term><def><p id="Par10">Vascular endothelial growth factor</p></def></def-item><def-item><term>TLR4</term><def><p id="Par11">Toll-like receptor 4</p></def></def-item><def-item><term>STAT3</term><def><p id="Par12">Signal transducer and activator of transcription 3</p></def></def-item><def-item><term>PDGF</term><def><p id="Par13">Platelet derived growth factor</p></def></def-item><def-item><term>RFA</term><def><p id="Par14">Radiofrequency ablation</p></def></def-item><def-item><term>TACE</term><def><p id="Par15">Transcatheter arterial chemoembolization</p></def></def-item><def-item><term>RCT</term><def><p id="Par16">Randomized controlled trial</p></def></def-item><def-item><term>MMC</term><def><p id="Par17">Mitomycin CDOX: doxorubicin</p></def></def-item><def-item><term>CTX</term><def><p id="Par18">Cyclophosphamide</p></def></def-item><def-item><term>5-FU</term><def><p id="Par19">5-Fluorouracil</p></def></def-item><def-item><term>PES</term><def><p id="Par20">Post embolism syndrome</p></def></def-item><def-item><term>ICIs</term><def><p id="Par21">Immune checkpoint inhibitors</p></def></def-item><def-item><term>PD1</term><def><p id="Par22">Anti-programmed cell death protein 1</p></def></def-item><def-item><term>PD-L1</term><def><p id="Par23">Programmed cell death-Ligand 1</p></def></def-item><def-item><term>DHZCP</term><def><p id="Par24">Dahuang Zhechong Pill</p></def></def-item><def-item><term>AE-SN</term><def><p id="Par25">Aqueous extract of Solanum nigrum</p></def></def-item><def-item><term>HGK</term><def><p id="Par26">Hydroxygenkwanin</p></def></def-item><def-item><term>NPPN</term><def><p id="Par27">Neutral polysaccharide from Panax notoginseng</p></def></def-item><def-item><term>BSHYJD</term><def><p id="Par28">Bushen huayu jiedu Recipe</p></def></def-item><def-item><term>WSTF</term><def><p id="Par29">Water-soluble total flavonoids from Isodon lophanthoides var. gerardianus (Benth.) H. Hara</p></def></def-item><def-item><term>YIV-906</term><def><p id="Par30">Huangqin Decoction</p></def></def-item><def-item><term>NF-&#x003ba;B</term><def><p id="Par31">Nuclear Factor kappa B</p></def></def-item><def-item><term>Bcl-2</term><def><p id="Par32">B-cell lymphoma-2</p></def></def-item><def-item><term>Bax</term><def><p id="Par33">Bcl-2-associated X</p></def></def-item><def-item><term>Bcl-xl</term><def><p id="Par34">B-cell lymphoma-extra large</p></def></def-item><def-item><term>TNF-&#x003b1;</term><def><p id="Par35">Tumor necrosis factor-&#x003b1;</p></def></def-item><def-item><term>IL-6</term><def><p id="Par36">Interleukin-6</p></def></def-item><def-item><term>IL-2</term><def><p id="Par37">Interleukin-2</p></def></def-item><def-item><term>OS</term><def><p id="Par38">Overall survival</p></def></def-item><def-item><term>Fas</term><def><p id="Par39">Factor associated suicide</p></def></def-item><def-item><term>FasL</term><def><p id="Par40">Factor associated suicide ligand</p></def></def-item><def-item><term>LC-3</term><def><p id="Par41">Light chain-3</p></def></def-item><def-item><term>PI3K</term><def><p id="Par42">Phosphatidylinositol 3 kinase</p></def></def-item><def-item><term>mTOR</term><def><p id="Par43">Mammalian target of rapamycin</p></def></def-item><def-item><term>PLD</term><def><p id="Par44">Pegylated liposomal DOX</p></def></def-item><def-item><term>ERK</term><def><p id="Par45">Extracellular regulated protein kinases</p></def></def-item><def-item><term>CRT</term><def><p id="Par46">CalreticulinHMGB1: high mobility group box 1</p></def></def-item><def-item><term>MMP</term><def><p id="Par47">Matrix metalloproteinase</p></def></def-item><def-item><term>PTTG1</term><def><p id="Par48">Pituitary tumor-transforming 1</p></def></def-item><def-item><term>MRP2</term><def><p id="Par49">Multidrug resistance-associated protein 2</p></def></def-item><def-item><term>CYR61</term><def><p id="Par50">Cysteine-rich61</p></def></def-item><def-item><term>OX1R</term><def><p id="Par51">Orexin 1 receptor</p></def></def-item><def-item><term>GHSR</term><def><p id="Par52">Growth hormone secretagogue receptor</p></def></def-item><def-item><term>NPY</term><def><p id="Par53">Neuropeptide Y</p></def></def-item><def-item><term>AGRP</term><def><p id="Par54">Agouti related neuropeptide</p></def></def-item><def-item><term>Ob-R</term><def><p id="Par55">Leptin receptor</p></def></def-item><def-item><term>POMC</term><def><p id="Par56">Pro-opiomelanocortin</p></def></def-item><def-item><term>CART</term><def><p id="Par57">Cocaine-and amphetamine-regulated transcript</p></def></def-item><def-item><term>P-gp</term><def><p id="Par58">P-glycoprotein</p></def></def-item><def-item><term>CM</term><def><p id="Par59">Condition medium</p></def></def-item><def-item><term>CCRK</term><def><p id="Par60">Cell cycle related kinase</p></def></def-item><def-item><term>TCF</term><def><p id="Par61">Tcell factor</p></def></def-item><def-item><term>TNFR</term><def><p id="Par62">Tumor necrosis factor receptor</p></def></def-item><def-item><term>MAPK</term><def><p id="Par63">Mitogen-activated protein kinase</p></def></def-item><def-item><term>JAK</term><def><p id="Par64">Janus Kinase</p></def></def-item><def-item><term>E-Cad</term><def><p id="Par65">E-cadherin</p></def></def-item><def-item><term>Vim</term><def><p id="Par66">Vimentin</p></def></def-item><def-item><term>C-FLIP</term><def><p id="Par67">Cellular FLICE-like inhibitory protein</p></def></def-item><def-item><term>ECM</term><def><p id="Par68">Extracellular matrix</p></def></def-item><def-item><term>MKK4</term><def><p id="Par69">Mitogen-Activated Protein Kinase Kinase 4</p></def></def-item><def-item><term>JNK</term><def><p id="Par70">C-Jun N-terminal kinase</p></def></def-item><def-item><term>uPA</term><def><p id="Par71">Urokinase plasminogen activator</p></def></def-item><def-item><term>HepG2-SR</term><def><p id="Par72">Sorafenib-resistant HCC cell line</p></def></def-item><def-item><term>LDH</term><def><p id="Par73">Lactate dehydrogenase</p></def></def-item><def-item><term>HIF-1&#x003b1;</term><def><p id="Par74">Hypoxic inducible factor 1&#x003b1;</p></def></def-item><def-item><term>FASN</term><def><p id="Par75">Fatty Acid Synthase</p></def></def-item><def-item><term>HDL-C</term><def><p id="Par76">High density liptein cholesterol</p></def></def-item><def-item><term>EMT</term><def><p id="Par77">Epithelial&#x02013;mesenchymal transition</p></def></def-item><def-item><term>IL1</term><def><p id="Par78">Interleukin-1</p></def></def-item><def-item><term>MyD88</term><def><p id="Par79">Myeloiddifferentiationfactor88</p></def></def-item><def-item><term>I&#x003ba;B-&#x003b1;</term><def><p id="Par80">Inhibitor of NF-&#x003ba;B alpha</p></def></def-item><def-item><term>EGF</term><def><p id="Par81">Epithelial growth factorHCPT: 10-Hydroxycamptothecin</p></def></def-item><def-item><term>MCP-1</term><def><p id="Par82">Monocyte chemoattractant protein-1</p></def></def-item><def-item><term>CXCL</term><def><p id="Par83">Chemokine (C-X-C motif) Ligand</p></def></def-item><def-item><term>TLR7</term><def><p id="Par84">Toll-like receptor 7</p></def></def-item><def-item><term>VEGFR</term><def><p id="Par85">Vascular endothelial growth factor receptor</p></def></def-item><def-item><term>R-HepG2</term><def><p id="Par86">Multidrug resistant HCC cell line</p></def></def-item><def-item><term>AANG</term><def><p id="Par87">Asiatic acid Naringenin</p></def></def-item><def-item><term>TGF-&#x003b2;</term><def><p id="Par88">Transforming growth factor-&#x003b2;</p></def></def-item><def-item><term>Smad</term><def><p id="Par89">Intracellular effectors of TGF-&#x003b2; signalling</p></def></def-item><def-item><term>HSP90</term><def><p id="Par90">Heat shock protein 90</p></def></def-item><def-item><term>HDACi</term><def><p id="Par91">Histone deacetylase inhibitor</p></def></def-item><def-item><term>HDACi-R</term><def><p id="Par92">HDACi-resistant</p></def></def-item><def-item><term>THM</term><def><p id="Par93">Traditional Herbal Medicine</p></def></def-item><def-item><term>ALT</term><def><p id="Par94">Alanine transaminase</p></def></def-item><def-item><term>AST</term><def><p id="Par95">Aspartate transaminase</p></def></def-item><def-item><term>DFS</term><def><p id="Par96">Disease-free survival</p></def></def-item><def-item><term>JLD</term><def><p id="Par97">Jian Pi Li gan decoction</p></def></def-item><def-item><term>CHHJ</term><def><p id="Par98">Chaihu-Huaji decoction</p></def></def-item><def-item><term>FFBM</term><def><p id="Par99">Compound cantharidin capsules</p></def></def-item><def-item><term>JLC</term><def><p id="Par100">Jinlong capsule</p></def></def-item><def-item><term>JD</term><def><p id="Par101">Jie-du granules</p></def></def-item><def-item><term>SOR</term><def><p id="Par102">Sorafenib</p></def></def-item><def-item><term>CHM</term><def><p id="Par103">Chinese herbal medicine</p></def></def-item><def-item><term>HR</term><def><p id="Par104">Hazard ratio</p></def></def-item><def-item><term>95%CI</term><def><p id="Par105">95% Confidence interval</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Lai Wei and Zeyu Wang contributed equally to this work</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors thank the Jilin Province Science and Technology Development for supporting this publication.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>WXQ and YZ: conceptualization. HYG, SKS, and MJL: investigation. LW, ZYW and WXQ: writing original draft, review and editing draft. YL and JLY: visualization. NCJ and XYL: supervision. YZ and DQZ: project administration, YZ: funding acquisition. All authors have read and agreed to the published version of the manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This research was supported by Jilin Province Science and Technology Development (No. 20210204077YY).</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>The data used for this study are included in the manuscript and additional file.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par134">Not applicable.</p></notes><notes><title>Consent for publication</title><p>Not applicable.</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Competing interests</title><p id="Par137">The authors declare that they have no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>H</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Laversanne</surname><given-names>M</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name></person-group><article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin.</source><year>2021</year><volume>71</volume><issue>3</issue><fpage>209</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.3322/caac.21660</pub-id><?supplied-pmid 33538338?><pub-id pub-id-type="pmid">33538338</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Xie</surname><given-names>WF</given-names></name></person-group><article-title>A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China</article-title><source>Br J Cancer.</source><year>2005</year><volume>92</volume><issue>3</issue><fpage>607</fpage><lpage>612</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6602333</pub-id><?supplied-pmid 15685242?><pub-id pub-id-type="pmid">15685242</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schietroma</surname><given-names>I</given-names></name><name><surname>Scheri</surname><given-names>GC</given-names></name><name><surname>Pinacchio</surname><given-names>C</given-names></name><name><surname>Statzu</surname><given-names>M</given-names></name><name><surname>Petruzziello</surname><given-names>A</given-names></name><name><surname>Vullo</surname><given-names>V</given-names></name></person-group><article-title>Hepatitis C virus and hepatocellular carcinoma: pathogenetic mechanisms and impact of direct-acting antivirals</article-title><source>Open Virol J.</source><year>2018</year><volume>12</volume><fpage>16</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.2174/1874357901812010016</pub-id><?supplied-pmid 29541275?><pub-id pub-id-type="pmid">29541275</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Kelley</surname><given-names>RK</given-names></name><name><surname>Villanueva</surname><given-names>A</given-names></name><name><surname>Singal</surname><given-names>AG</given-names></name><name><surname>Pikarsky</surname><given-names>E</given-names></name><name><surname>Roayaie</surname><given-names>S</given-names></name><name><surname>Lencioni</surname><given-names>R</given-names></name><name><surname>Koike</surname><given-names>K</given-names></name><name><surname>Zucman-Rossi</surname><given-names>J</given-names></name><name><surname>Finn</surname><given-names>RS</given-names></name></person-group><article-title>Hepatocellular carcinoma</article-title><source>Nat Rev Dis Primers</source><year>2021</year><volume>7</volume><issue>1</issue><fpage>6</fpage><pub-id pub-id-type="doi">10.1038/s41572-020-00240-3</pub-id><?supplied-pmid 33479224?><pub-id pub-id-type="pmid">33479224</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhar</surname><given-names>D</given-names></name><name><surname>Baglieri</surname><given-names>J</given-names></name><name><surname>Kisseleva</surname><given-names>T</given-names></name><name><surname>Brenner</surname><given-names>DA</given-names></name></person-group><article-title>Mechanisms of liver fibrosis and its role in liver cancer</article-title><source>Exp Biol Med (Maywood).</source><year>2020</year><volume>245</volume><issue>2</issue><fpage>96</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1177/1535370219898141</pub-id><?supplied-pmid 31924111?><pub-id pub-id-type="pmid">31924111</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sagnelli</surname><given-names>E</given-names></name><name><surname>Macera</surname><given-names>M</given-names></name><name><surname>Russo</surname><given-names>A</given-names></name><name><surname>Coppola</surname><given-names>N</given-names></name><name><surname>Sagnelli</surname><given-names>C</given-names></name></person-group><article-title>Epidemiological and etiological variations in hepatocellular carcinoma</article-title><source>Infection</source><year>2020</year><volume>48</volume><issue>1</issue><fpage>7</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1007/s15010-019-01345-y</pub-id><?supplied-pmid 31347138?><pub-id pub-id-type="pmid">31347138</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>YX</given-names></name><name><surname>Yang</surname><given-names>TW</given-names></name><name><surname>Yin</surname><given-names>JM</given-names></name><name><surname>Yang</surname><given-names>PX</given-names></name><name><surname>Kou</surname><given-names>BX</given-names></name><name><surname>Chai</surname><given-names>MY</given-names></name><name><surname>Liu</surname><given-names>XN</given-names></name><name><surname>Chen</surname><given-names>DX</given-names></name></person-group><article-title>Progress and prospects of biomarkers in&#x000a0;primary liver cancer (Review)</article-title><source>Int J Oncol.</source><year>2020</year><volume>57</volume><issue>1</issue><fpage>54</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.3892/ijo.2020.5035</pub-id><?supplied-pmid 32236573?><pub-id pub-id-type="pmid">32236573</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruix</surname><given-names>J</given-names></name><name><surname>Reig</surname><given-names>M</given-names></name><name><surname>Sherman</surname><given-names>M</given-names></name></person-group><article-title>Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma</article-title><source>Gastroenterology</source><year>2016</year><volume>150</volume><issue>4</issue><fpage>835</fpage><lpage>853</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2015.12.041</pub-id><?supplied-pmid 26795574?><pub-id pub-id-type="pmid">26795574</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Cong</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zeng</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Bie</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Wen</surname><given-names>T</given-names></name><name><surname>Han</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Ren</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Zeng</surname><given-names>Z</given-names></name><name><surname>Liang</surname><given-names>P</given-names></name><name><surname>Liang</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Yan</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Ji</surname><given-names>Y</given-names></name><name><surname>Yun</surname><given-names>J</given-names></name><name><surname>Cai</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Cheng</surname><given-names>W</given-names></name><name><surname>Cheng</surname><given-names>S</given-names></name><name><surname>Dai</surname><given-names>C</given-names></name><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>Hua</surname><given-names>B</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Jia</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Lv</surname><given-names>G</given-names></name><name><surname>Mao</surname><given-names>Y</given-names></name><name><surname>Peng</surname><given-names>T</given-names></name><name><surname>Ren</surname><given-names>W</given-names></name><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Shi</surname><given-names>G</given-names></name><name><surname>Tao</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Xiang</surname><given-names>B</given-names></name><name><surname>Xing</surname><given-names>B</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Ye</surname><given-names>S</given-names></name><name><surname>Yin</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Dai</surname><given-names>Z</given-names></name><name><surname>Teng</surname><given-names>G</given-names></name><name><surname>Cai</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Cai</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Shen</surname><given-names>F</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Dong</surname><given-names>J</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name></person-group><article-title>Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma</article-title><source>Liver Cancer.</source><year>2020</year><volume>9</volume><issue>6</issue><fpage>682</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1159/000509424</pub-id><?supplied-pmid 33442540?><pub-id pub-id-type="pmid">33442540</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>YS</given-names></name><name><surname>Lim</surname><given-names>HK</given-names></name><name><surname>Rhim</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>MW</given-names></name></person-group><article-title>Ablation of hepatocellular carcinoma</article-title><source>Best Pract Res Clin Gastroenterol</source><year>2014</year><volume>28</volume><issue>5</issue><fpage>897</fpage><lpage>908</lpage><pub-id pub-id-type="doi">10.1016/j.bpg.2014.08.011</pub-id><?supplied-pmid 25260316?><pub-id pub-id-type="pmid">25260316</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ju</surname><given-names>MR</given-names></name><name><surname>Yopp</surname><given-names>AC</given-names></name></person-group><article-title>Surgical resection of early stage hepatocellular carcinoma: balancing tumor biology with the host liver</article-title><source>Chin Clin Oncol</source><year>2021</year><volume>10</volume><issue>1</issue><fpage>5</fpage><pub-id pub-id-type="doi">10.1037/cco-20-130</pub-id><?supplied-pmid 32434346?><pub-id pub-id-type="pmid">32434346</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewandowski</surname><given-names>RJ</given-names></name><name><surname>Gabr</surname><given-names>A</given-names></name><name><surname>Abouchaleh</surname><given-names>N</given-names></name><name><surname>Ali</surname><given-names>R</given-names></name><name><surname>Asadi</surname><given-names>AA</given-names></name><name><surname>Mora</surname><given-names>RA</given-names></name><name><surname>Kulik</surname><given-names>L</given-names></name><name><surname>Ganger</surname><given-names>D</given-names></name><name><surname>Desai</surname><given-names>K</given-names></name><name><surname>Thornburg</surname><given-names>B</given-names></name><name><surname>Mouli</surname><given-names>S</given-names></name><name><surname>Hickey</surname><given-names>R</given-names></name><name><surname>Caicedo</surname><given-names>JC</given-names></name><name><surname>Abecassis</surname><given-names>M</given-names></name><name><surname>Riaz</surname><given-names>A</given-names></name><name><surname>Salem</surname><given-names>R</given-names></name></person-group><article-title>Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma</article-title><source>Radiology</source><year>2018</year><volume>287</volume><issue>3</issue><fpage>1050</fpage><lpage>1058</lpage><pub-id pub-id-type="doi">10.1148/radiol.2018171768</pub-id><?supplied-pmid 29688155?><pub-id pub-id-type="pmid">29688155</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sapisochin</surname><given-names>G</given-names></name><name><surname>Bruix</surname><given-names>J</given-names></name></person-group><article-title>Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2017</year><volume>14</volume><issue>4</issue><fpage>203</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1038/nrgastro.2016.193</pub-id><?supplied-pmid 28053342?><pub-id pub-id-type="pmid">28053342</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name></person-group><article-title>Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system</article-title><source>World J Gastroenterol</source><year>2015</year><volume>21</volume><issue>36</issue><fpage>10327</fpage><lpage>10335</lpage><pub-id pub-id-type="doi">10.3748/wjg.v21.i36.10327</pub-id><?supplied-pmid 26420959?><pub-id pub-id-type="pmid">26420959</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>HL</given-names></name><name><surname>Bloomston</surname><given-names>M</given-names></name></person-group><article-title>Hepatic artery infusional chemotherapy</article-title><source>Surg Clin North Am</source><year>2016</year><volume>96</volume><issue>2</issue><fpage>341</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1016/j.suc.2015.11.002</pub-id><?supplied-pmid 27017868?><pub-id pub-id-type="pmid">27017868</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Couri</surname><given-names>T</given-names></name><name><surname>Pillai</surname><given-names>A</given-names></name></person-group><article-title>Goals and targets for personalized therapy for HCC</article-title><source>Hepatol Int</source><year>2019</year><volume>13</volume><issue>2</issue><fpage>125</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1007/s12072-018-9919-1</pub-id><?supplied-pmid 30600478?><pub-id pub-id-type="pmid">30600478</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>AL</given-names></name><name><surname>Hsu</surname><given-names>C</given-names></name><name><surname>Chan</surname><given-names>SL</given-names></name><name><surname>Choo</surname><given-names>SP</given-names></name><name><surname>Kudo</surname><given-names>M</given-names></name></person-group><article-title>Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma</article-title><source>J Hepatol</source><year>2020</year><volume>72</volume><issue>2</issue><fpage>307</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2019.09.025</pub-id><?supplied-pmid 31954494?><pub-id pub-id-type="pmid">31954494</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yongkun</surname><given-names>S</given-names></name></person-group><article-title>Interpretation of 2018 CSCO guidelines for the diagnosis and treatment of primary liver cancer - systemic treatment</article-title><source>Electronic Journal of liver Tumor</source><year>2018</year><volume>3</volume><fpage>11</fpage><lpage>14</lpage></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKinley</surname><given-names>SK</given-names></name><name><surname>Chawla</surname><given-names>A</given-names></name><name><surname>Ferrone</surname><given-names>CR</given-names></name></person-group><article-title>Inoperable biliary tract and primary liver tumors: palliative treatment options</article-title><source>Surg Oncol Clin N Am</source><year>2019</year><volume>28</volume><issue>4</issue><fpage>745</fpage><lpage>762</lpage><pub-id pub-id-type="doi">10.1016/j.soc.2019.06.009</pub-id><?supplied-pmid 31472917?><pub-id pub-id-type="pmid">31472917</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhardwaj</surname><given-names>N</given-names></name><name><surname>Strickland</surname><given-names>AD</given-names></name><name><surname>Ahmad</surname><given-names>F</given-names></name><name><surname>Atanesyan</surname><given-names>L</given-names></name><name><surname>West</surname><given-names>K</given-names></name><name><surname>Lloyd</surname><given-names>DM</given-names></name></person-group><article-title>A comparative histological evaluation of the ablations produced by microwave, cryotherapy and radiofrequency in the liver</article-title><source>Pathology</source><year>2009</year><volume>41</volume><issue>2</issue><fpage>168</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1080/00313020802579292</pub-id><?supplied-pmid 19152189?><pub-id pub-id-type="pmid">19152189</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blackburn</surname><given-names>H</given-names></name><name><surname>West</surname><given-names>S</given-names></name></person-group><article-title>Management of postembolization syndrome following hepatic transarterial chemoembolization for primary or metastatic liver cancer</article-title><source>Cancer Nurs</source><year>2016</year><volume>39</volume><issue>5</issue><fpage>E1</fpage><lpage>e18</lpage><pub-id pub-id-type="doi">10.1097/ncc.0000000000000302</pub-id><?supplied-pmid 26484962?><pub-id pub-id-type="pmid">26484962</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikeda</surname><given-names>M</given-names></name><name><surname>Morizane</surname><given-names>C</given-names></name><name><surname>Ueno</surname><given-names>M</given-names></name><name><surname>Okusaka</surname><given-names>T</given-names></name><name><surname>Ishii</surname><given-names>H</given-names></name><name><surname>Furuse</surname><given-names>J</given-names></name></person-group><article-title>Chemotherapy for hepatocellular carcinoma: current status and future perspectives</article-title><source>Jpn J Clin Oncol</source><year>2018</year><volume>48</volume><issue>2</issue><fpage>103</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1093/jjco/hyx180</pub-id><?supplied-pmid 29253194?><pub-id pub-id-type="pmid">29253194</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>YJ</given-names></name><name><surname>Zheng</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>HY</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name></person-group><article-title>New knowledge of the mechanisms of sorafenib resistance in liver cancer</article-title><source>Acta Pharmacol Sin</source><year>2017</year><volume>38</volume><issue>5</issue><fpage>614</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1038/aps.2017.5</pub-id><?supplied-pmid 28344323?><pub-id pub-id-type="pmid">28344323</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Khoueiry</surname><given-names>AB</given-names></name><name><surname>Sangro</surname><given-names>B</given-names></name><name><surname>Yau</surname><given-names>T</given-names></name><name><surname>Crocenzi</surname><given-names>TS</given-names></name><name><surname>Kudo</surname><given-names>M</given-names></name><name><surname>Hsu</surname><given-names>C</given-names></name><name><surname>Kim</surname><given-names>TY</given-names></name><name><surname>Choo</surname><given-names>SP</given-names></name><name><surname>Trojan</surname><given-names>J</given-names></name><name><surname>Welling</surname><given-names>THR</given-names></name><name><surname>Meyer</surname><given-names>T</given-names></name><name><surname>Kang</surname><given-names>YK</given-names></name><name><surname>Yeo</surname><given-names>W</given-names></name><name><surname>Chopra</surname><given-names>A</given-names></name><name><surname>Anderson</surname><given-names>J</given-names></name><name><surname>Dela</surname><given-names>Cruz C</given-names></name><name><surname>Lang</surname><given-names>L</given-names></name><name><surname>Neely</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Dastani</surname><given-names>HB</given-names></name><name><surname>Melero</surname><given-names>I</given-names></name></person-group><article-title>Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial</article-title><source>Lancet</source><year>2017</year><volume>389</volume><issue>10088</issue><fpage>2492</fpage><lpage>2502</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(17)31046-2</pub-id><?supplied-pmid 28434648?><pub-id pub-id-type="pmid">28434648</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>JJ</given-names></name><name><surname>Liang</surname><given-names>Q</given-names></name><name><surname>Sun</surname><given-names>GC</given-names></name></person-group><article-title>Traditional Chinese medicine for prevention and treatment of hepatocellular carcinoma: a focus on epithelial-mesenchymal transition</article-title><source>J Integr Med</source><year>2021</year><volume>19</volume><issue>6</issue><fpage>469</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1016/j.joim.2021.08.004</pub-id><?supplied-pmid 34538644?><pub-id pub-id-type="pmid">34538644</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>KY</given-names></name><name><surname>Du</surname><given-names>SL</given-names></name><name><surname>Wang</surname><given-names>QL</given-names></name><name><surname>Zhang</surname><given-names>YF</given-names></name><name><surname>Song</surname><given-names>HY</given-names></name></person-group><article-title>Traditional Chinese medicine targeting cancer stem cells as an alternative treatment for hepatocellular carcinoma</article-title><source>J Integr Med</source><year>2020</year><volume>18</volume><issue>3</issue><fpage>196</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1016/j.joim.2020.02.002</pub-id><?supplied-pmid 32067923?><pub-id pub-id-type="pmid">32067923</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>HT</given-names></name><name><surname>Meng</surname><given-names>YB</given-names></name><name><surname>Zhai</surname><given-names>XF</given-names></name><name><surname>Cheng</surname><given-names>BB</given-names></name><name><surname>Yu</surname><given-names>SS</given-names></name><name><surname>Yao</surname><given-names>M</given-names></name><name><surname>Yin</surname><given-names>HX</given-names></name><name><surname>Wan</surname><given-names>XY</given-names></name><name><surname>Yang</surname><given-names>YK</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Shen</surname><given-names>F</given-names></name><name><surname>Ling</surname><given-names>CQ</given-names></name></person-group><article-title>Comparable effects of jiedu granule, a compound chinese herbal medicine, and sorafenib for advanced hepatocellular carcinoma: a prospective multicenter cohort study</article-title><source>J Integr Med</source><year>2020</year><volume>18</volume><issue>4</issue><fpage>319</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1016/j.joim.2020.05.003</pub-id><?supplied-pmid 32532615?><pub-id pub-id-type="pmid">32532615</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>JS</given-names></name><name><surname>Huo</surname><given-names>CY</given-names></name><name><surname>Cao</surname><given-names>HH</given-names></name><name><surname>Fan</surname><given-names>CL</given-names></name><name><surname>Hu</surname><given-names>JY</given-names></name><name><surname>Deng</surname><given-names>LJ</given-names></name><name><surname>Lu</surname><given-names>ZB</given-names></name><name><surname>Yang</surname><given-names>HY</given-names></name><name><surname>Yu</surname><given-names>LZ</given-names></name><name><surname>Mo</surname><given-names>ZX</given-names></name><name><surname>Yu</surname><given-names>ZL</given-names></name></person-group><article-title>Aloperine induces apoptosis and G2/M cell cycle arrest in hepatocellular carcinoma cells through the PI3K/Akt signaling pathway</article-title><source>Phytomedicine</source><year>2019</year><volume>61</volume><fpage>152843</fpage><pub-id pub-id-type="doi">10.1016/j.phymed.2019.152843</pub-id><?supplied-pmid 31039533?><pub-id pub-id-type="pmid">31039533</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Song</surname><given-names>N</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Hui</surname><given-names>L</given-names></name><name><surname>Sang</surname><given-names>C</given-names></name></person-group><article-title>Lappaconitine sulfate inhibits proliferation and induces apoptosis in human hepatocellular carcinoma hepg2 cells through the reactive oxygen species-dependent mitochondrial pathway</article-title><source>Pharmacology</source><year>2020</year><volume>105</volume><issue>11&#x02013;12</issue><fpage>705</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1159/000506081</pub-id><?supplied-pmid 32062649?><pub-id pub-id-type="pmid">32062649</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Ji</surname><given-names>L</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Sheng</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Feng</surname><given-names>H</given-names></name></person-group><article-title>Bufalin stimulates antitumor immune response by driving tumor-infiltrating macrophage toward M1 phenotype in hepatocellular carcinoma</article-title><source>J Immunother Cancer</source><year>2022</year><pub-id pub-id-type="doi">10.1136/jitc-2021-004297</pub-id><?supplied-pmid 35858707?><pub-id pub-id-type="pmid">35858707</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wen</surname><given-names>PH</given-names></name><name><surname>Zhang</surname><given-names>XX</given-names></name><name><surname>Dai</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>Q</given-names></name></person-group><article-title>Breviscapine ameliorates CCl4-induced liver injury in mice through inhibiting inflammatory apoptotic response and ROS generation</article-title><source>Int J Mol Med</source><year>2018</year><volume>42</volume><issue>2</issue><fpage>755</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.3892/ijmm.2018.3651</pub-id><?supplied-pmid 29717768?><pub-id pub-id-type="pmid">29717768</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lan</surname><given-names>T</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Weng</surname><given-names>Q</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Tian</surname><given-names>S</given-names></name><name><surname>Ding</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Luo</surname><given-names>D</given-names></name><name><surname>Xiao</surname><given-names>X</given-names></name><name><surname>Piao</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>Q</given-names></name><name><surname>Rong</surname><given-names>X</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name></person-group><article-title>Breviscapine alleviates NASH by inhibiting TGF-&#x003b2;-activated kinase 1-dependent signaling</article-title><source>Hepatology</source><year>2022</year><volume>76</volume><issue>1</issue><fpage>155</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1002/hep.32221</pub-id><?supplied-pmid 34717002?><pub-id pub-id-type="pmid">34717002</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Min</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Qi</surname><given-names>H</given-names></name></person-group><article-title>Astragaloside IV inhibits the progression of liver cancer by modulating macrophage polarization through the TLR4/NF-&#x003ba;B/STAT3 signaling pathway</article-title><source>Am J Transl Res</source><year>2022</year><volume>14</volume><issue>3</issue><fpage>1551</fpage><lpage>1566</lpage><?supplied-pmid 35422920?><pub-id pub-id-type="pmid">35422920</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Tang</surname><given-names>D</given-names></name><name><surname>Zang</surname><given-names>W</given-names></name><name><surname>Yin</surname><given-names>G</given-names></name><name><surname>Dai</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>YU</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Hoffman</surname><given-names>RM</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name></person-group><article-title>Synergistic inhibitory effect of traditional chinese medicine astragaloside iv and curcumin on tumor growth and angiogenesis in an orthotopic nude-mouse model of human hepatocellular carcinoma</article-title><source>Anticancer Res</source><year>2017</year><volume>37</volume><issue>2</issue><fpage>465</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1873/anticanres.11338</pub-id><?supplied-pmid 28179291?><pub-id pub-id-type="pmid">28179291</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Dang</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name></person-group><article-title>Effects of adjuvant traditional Chinese medicine therapy on long-term survival in patients with hepatocellular carcinoma</article-title><source>Phytomedicine</source><year>2019</year><volume>62</volume><fpage>152930</fpage><pub-id pub-id-type="doi">10.1016/j.phymed.2019.152930</pub-id><?supplied-pmid 31128485?><pub-id pub-id-type="pmid">31128485</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tenconi</surname><given-names>E</given-names></name><name><surname>Rigali</surname><given-names>S</given-names></name></person-group><article-title>Self-resistance mechanisms to DNA-damaging antitumor antibiotics in actinobacteria</article-title><source>Curr Opin Microbiol</source><year>2018</year><volume>45</volume><fpage>100</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1016/j.mib.2018.03.003</pub-id><?supplied-pmid 29642052?><pub-id pub-id-type="pmid">29642052</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tacar</surname><given-names>O</given-names></name><name><surname>Sriamornsak</surname><given-names>P</given-names></name><name><surname>Dass</surname><given-names>CR</given-names></name></person-group><article-title>Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems</article-title><source>J Pharm Pharmacol</source><year>2013</year><volume>65</volume><issue>2</issue><fpage>157</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1111/j.2042-7158.2012.01567.x</pub-id><?supplied-pmid 23278683?><pub-id pub-id-type="pmid">23278683</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>E</given-names></name><name><surname>Scurr</surname><given-names>M</given-names></name><name><surname>Campbell</surname><given-names>E</given-names></name><name><surname>Jones</surname><given-names>E</given-names></name><name><surname>Godkin</surname><given-names>A</given-names></name><name><surname>Gallimore</surname><given-names>A</given-names></name></person-group><article-title>T-cell modulation by cyclophosphamide for tumour therapy</article-title><source>Immunology</source><year>2018</year><volume>154</volume><issue>1</issue><fpage>62</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1111/imm.12913</pub-id><?supplied-pmid 29460448?><pub-id pub-id-type="pmid">29460448</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kogure</surname><given-names>T</given-names></name><name><surname>Ueno</surname><given-names>Y</given-names></name><name><surname>Iwasaki</surname><given-names>T</given-names></name><name><surname>Shimosegawa</surname><given-names>T</given-names></name></person-group><article-title>The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors</article-title><source>Cancer Chemother Pharmacol</source><year>2004</year><volume>53</volume><issue>4</issue><fpage>296</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1007/s00280-003-0725-6</pub-id><?supplied-pmid 14689231?><pub-id pub-id-type="pmid">14689231</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>More</surname><given-names>LA</given-names></name><name><surname>Lane</surname><given-names>S</given-names></name><name><surname>Asnani</surname><given-names>A</given-names></name></person-group><article-title>5-FU cardiotoxicity: vasospasm, myocarditis, and sudden death</article-title><source>Curr Cardiol Rep</source><year>2021</year><volume>23</volume><issue>3</issue><fpage>17</fpage><pub-id pub-id-type="doi">10.1007/s11886-021-01441-2</pub-id><?supplied-pmid 33537861?><pub-id pub-id-type="pmid">33537861</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shirani</surname><given-names>K</given-names></name><name><surname>Hassani</surname><given-names>FV</given-names></name><name><surname>Razavi-Azarkhiavi</surname><given-names>K</given-names></name><name><surname>Heidari</surname><given-names>S</given-names></name><name><surname>Zanjani</surname><given-names>BR</given-names></name><name><surname>Karimi</surname><given-names>G</given-names></name></person-group><article-title>Phytotrapy of cyclophosphamide-induced immunosuppression</article-title><source>Environ Toxicol Pharmacol</source><year>2015</year><volume>39</volume><issue>3</issue><fpage>1262</fpage><lpage>1275</lpage><pub-id pub-id-type="doi">10.1016/j.etap.2015.04.012</pub-id><?supplied-pmid 26026872?><pub-id pub-id-type="pmid">26026872</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patra</surname><given-names>K</given-names></name><name><surname>Bose</surname><given-names>S</given-names></name><name><surname>Sarkar</surname><given-names>S</given-names></name><name><surname>Rakshit</surname><given-names>J</given-names></name><name><surname>Jana</surname><given-names>S</given-names></name><name><surname>Mukherjee</surname><given-names>A</given-names></name><name><surname>Roy</surname><given-names>A</given-names></name><name><surname>Mandal</surname><given-names>DP</given-names></name><name><surname>Bhattacharjee</surname><given-names>S</given-names></name></person-group><article-title>Amelioration of cyclophosphamide induced myelosuppression and oxidative stress by cinnamic acid</article-title><source>Chem Biol Inter</source><year>2012</year><volume>195</volume><issue>3</issue><fpage>231</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1016/j.cbi.2012.01.001</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fong</surname><given-names>CW</given-names></name></person-group><article-title>Platinum based radiochemotherapies: Free radical mechanisms and radiotherapy sensitizers</article-title><source>Free Radic Biol Med</source><year>2016</year><volume>99</volume><fpage>99</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2016.07.006</pub-id><?supplied-pmid 27417937?><pub-id pub-id-type="pmid">27417937</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dasari</surname><given-names>S</given-names></name><name><surname>Tchounwou</surname><given-names>PB</given-names></name></person-group><article-title>Cisplatin in cancer therapy: molecular mechanisms of action</article-title><source>Eur J Pharmacol</source><year>2014</year><volume>740</volume><fpage>364</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2014.07.025</pub-id><?supplied-pmid 25058905?><pub-id pub-id-type="pmid">25058905</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Montal</surname><given-names>R</given-names></name><name><surname>Sia</surname><given-names>D</given-names></name><name><surname>Finn</surname><given-names>RS</given-names></name></person-group><article-title>Molecular therapies and precision medicine for hepatocellular carcinoma</article-title><source>Nat Rev Clin Oncol</source><year>2018</year><volume>15</volume><issue>10</issue><fpage>599</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1038/s41571-018-0073-4</pub-id><?supplied-pmid 30061739?><pub-id pub-id-type="pmid">30061739</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oun</surname><given-names>R</given-names></name><name><surname>Moussa</surname><given-names>YE</given-names></name><name><surname>Wheate</surname><given-names>NJ</given-names></name></person-group><article-title>The side effects of platinum-based chemotherapy drugs: a review for chemists</article-title><source>Dalton Trans</source><year>2018</year><volume>47</volume><issue>19</issue><fpage>6645</fpage><lpage>6653</lpage><pub-id pub-id-type="doi">10.1039/c8dt00838h</pub-id><?supplied-pmid 29632935?><pub-id pub-id-type="pmid">29632935</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cabral</surname><given-names>LKD</given-names></name><name><surname>Tiribelli</surname><given-names>C</given-names></name><name><surname>Sukowati</surname><given-names>CHC</given-names></name></person-group><article-title>Sorafenib resistance in hepatocellular carcinoma: the relevance of genetic heterogeneity</article-title><source>Cancers</source><year>2020</year><pub-id pub-id-type="doi">10.3390/cancers12061576</pub-id><?supplied-pmid 33353109?><pub-id pub-id-type="pmid">33353109</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kudo</surname><given-names>M</given-names></name><name><surname>Finn</surname><given-names>RS</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Han</surname><given-names>KH</given-names></name><name><surname>Ikeda</surname><given-names>K</given-names></name><name><surname>Piscaglia</surname><given-names>F</given-names></name><name><surname>Baron</surname><given-names>A</given-names></name><name><surname>Park</surname><given-names>JW</given-names></name><name><surname>Han</surname><given-names>G</given-names></name><name><surname>Jassem</surname><given-names>J</given-names></name><name><surname>Blanc</surname><given-names>JF</given-names></name><name><surname>Vogel</surname><given-names>A</given-names></name><name><surname>Komov</surname><given-names>D</given-names></name><name><surname>Evans</surname><given-names>TRJ</given-names></name><name><surname>Lopez</surname><given-names>C</given-names></name><name><surname>Dutcus</surname><given-names>C</given-names></name><name><surname>Guo</surname><given-names>M</given-names></name><name><surname>Saito</surname><given-names>K</given-names></name><name><surname>Kraljevic</surname><given-names>S</given-names></name><name><surname>Tamai</surname><given-names>T</given-names></name><name><surname>Ren</surname><given-names>M</given-names></name><name><surname>Cheng</surname><given-names>AL</given-names></name></person-group><article-title>Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial</article-title><source>Lancet</source><year>2018</year><volume>391</volume><issue>10126</issue><fpage>1163</fpage><lpage>1173</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(18)30207-1</pub-id><?supplied-pmid 29433850?><pub-id pub-id-type="pmid">29433850</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donisi</surname><given-names>C</given-names></name><name><surname>Puzzoni</surname><given-names>M</given-names></name><name><surname>Ziranu</surname><given-names>P</given-names></name><name><surname>Lai</surname><given-names>E</given-names></name><name><surname>Mariani</surname><given-names>S</given-names></name><name><surname>Saba</surname><given-names>G</given-names></name><name><surname>Impera</surname><given-names>V</given-names></name><name><surname>Dubois</surname><given-names>M</given-names></name><name><surname>Persano</surname><given-names>M</given-names></name><name><surname>Migliari</surname><given-names>M</given-names></name><name><surname>Pretta</surname><given-names>A</given-names></name><name><surname>Liscia</surname><given-names>N</given-names></name><name><surname>Astara</surname><given-names>G</given-names></name><name><surname>Scartozzi</surname><given-names>M</given-names></name></person-group><article-title>Immune Checkpoint Inhibitors in the Treatment of HCC</article-title><source>Front Oncol</source><year>2020</year><volume>10</volume><fpage>601240</fpage><pub-id pub-id-type="doi">10.3389/fonc.2020.601240</pub-id><?supplied-pmid 33585218?><pub-id pub-id-type="pmid">33585218</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>XH</given-names></name><name><surname>Geng</surname><given-names>LY</given-names></name><name><surname>Jiang</surname><given-names>PP</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Nan</surname><given-names>KJ</given-names></name><name><surname>Yao</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>LL</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Qin</surname><given-names>TJ</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name></person-group><article-title>The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors</article-title><source>J Exp Clin Cancer Res</source><year>2020</year><volume>39</volume><issue>1</issue><fpage>284</fpage><pub-id pub-id-type="doi">10.1186/s13046-020-01749-x</pub-id><?supplied-pmid 33317597?><pub-id pub-id-type="pmid">33317597</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hau</surname><given-names>DM</given-names></name><name><surname>Chen</surname><given-names>TH</given-names></name><name><surname>Cheng</surname><given-names>JF</given-names></name><name><surname>You</surname><given-names>JS</given-names></name></person-group><article-title>Combined therapy of mitomycin C and Chinese medical herbs on experimental liver cancer</article-title><source>Am J Chinese Med</source><year>1993</year><volume>21</volume><issue>1</issue><fpage>51</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1142/s0192415x93000078</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>You</surname><given-names>J-S</given-names></name><name><surname>Kau</surname><given-names>D-M</given-names></name><name><surname>Chen</surname><given-names>K-T</given-names></name><name><surname>Huang</surname><given-names>H-F</given-names></name></person-group><article-title>Combined effects of chuling (Polyporus umbellatus) extract and mitomycin C on experimental liver cancer</article-title><source>Am J Chinese Med</source><year>1994</year><volume>22</volume><issue>1</issue><fpage>19</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1142/s0192415x94000048</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>You</surname><given-names>JS</given-names></name><name><surname>Huang</surname><given-names>HF</given-names></name><name><surname>Hau</surname><given-names>DM</given-names></name></person-group><article-title>Effects of Xuefu Zhuyu Tang and mitomycin C on liver tumors in mice</article-title><source>Chang Gung Med J</source><year>2003</year><volume>26</volume><issue>6</issue><fpage>417</fpage><lpage>424</lpage><?supplied-pmid 12956288?><pub-id pub-id-type="pmid">12956288</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>YH</given-names></name><name><surname>Qin</surname><given-names>HY</given-names></name><name><surname>Zhong</surname><given-names>YY</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>HJ</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>LL</given-names></name><name><surname>Tang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>YL</given-names></name><name><surname>Qian</surname><given-names>ZY</given-names></name><name><surname>Li</surname><given-names>HY</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name></person-group><article-title>Neutral polysaccharide from Panax notoginseng enhanced cyclophosphamide antitumor efficacy in hepatoma H22-bearing mice</article-title><source>BMC Cancer</source><year>2021</year><volume>21</volume><issue>1</issue><fpage>37</fpage><pub-id pub-id-type="doi">10.1186/s12885-020-07742-z</pub-id><?supplied-pmid 33413214?><pub-id pub-id-type="pmid">33413214</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xi</surname><given-names>S</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Minuk</surname><given-names>GY</given-names></name><name><surname>Shi</surname><given-names>M</given-names></name><name><surname>Fu</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Yue</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>The combination effects of Shen-Ling-Bai-Zhu on promoting apoptosis of transplanted H-22 hepatocellular carcinoma in mice receiving chemotherapy</article-title><source>J Ethnopharmacol</source><year>2016</year><volume>190</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2016.05.055</pub-id><?supplied-pmid 27235019?><pub-id pub-id-type="pmid">27235019</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Qiu</surname><given-names>M</given-names></name><name><surname>Cheng</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Yuan</surname><given-names>W</given-names></name></person-group><article-title>Shengbai decoction enhances the anti-tumor efficacy of cyclophosphamide on hepatoma 22-bearing mice</article-title><source>Biomed Pharmacother</source><year>2021</year><pub-id pub-id-type="doi">10.1016/j.biopha.2021.111775</pub-id><?supplied-pmid 35062072?><pub-id pub-id-type="pmid">35062072</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>J-x</surname><given-names>Zhai</given-names></name><name><surname>Z-h</surname><given-names>Song</given-names></name><name><surname>Chang</surname><given-names>H</given-names></name><name><surname>Y-w</surname><given-names>Wang</given-names></name><name><surname>Han</surname><given-names>N</given-names></name><name><surname>Z-h</surname><given-names>Liu</given-names></name><name><surname>Yin</surname><given-names>J</given-names></name></person-group><article-title>He-Wei Granule enhances anti-tumor activity of cyclophosphamide by changing tumor microenvironment</article-title><source>Chinese Herbal Med</source><year>2021</year><pub-id pub-id-type="doi">10.1016/j.chmed.2021.10.002</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>M</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name></person-group><article-title>Icaritin exacerbates mitophagy and synergizes with doxorubicin to induce immunogenic cell death in hepatocellular carcinoma</article-title><source>ACS Nano</source><year>2020</year><volume>14</volume><issue>4</issue><fpage>4816</fpage><lpage>4828</lpage><pub-id pub-id-type="doi">10.1021/acsnano.0c00708</pub-id><?supplied-pmid 32188241?><pub-id pub-id-type="pmid">32188241</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abo Mansour</surname><given-names>HE</given-names></name><name><surname>El-Batsh</surname><given-names>MM</given-names></name><name><surname>Badawy</surname><given-names>NS</given-names></name><name><surname>Mehanna</surname><given-names>ET</given-names></name><name><surname>Mesbah</surname><given-names>NM</given-names></name><name><surname>Abo-Elmatty</surname><given-names>DM</given-names></name></person-group><article-title>Ginger extract loaded into chitosan nanoparticles enhances cytotoxicity and reduces cardiotoxicity of doxorubicin in hepatocellular carcinoma in mice</article-title><source>Nutr Cancer</source><year>2020</year><pub-id pub-id-type="doi">10.1080/01635581.2020.1823436</pub-id><?supplied-pmid 32972241?><pub-id pub-id-type="pmid">32972241</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>H</given-names></name></person-group><article-title>Dihydroartemisinin sensitizes mutant p53 (R248Q)-expressing hepatocellular carcinoma cells to doxorubicin by inhibiting P-gp expression</article-title><source>Biomed Res Int</source><year>2019</year><volume>2019</volume><fpage>8207056</fpage><pub-id pub-id-type="doi">10.1155/2019/8207056</pub-id><?supplied-pmid 31976328?><pub-id pub-id-type="pmid">31976328</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>R</given-names></name><name><surname>Gupta</surname><given-names>P</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>Liao</surname><given-names>L</given-names></name><name><surname>Xie</surname><given-names>YA</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>ZS</given-names></name><name><surname>Liang</surname><given-names>G</given-names></name></person-group><article-title>The epigallocatechin gallate derivative Y(6) reverses drug resistance mediated by the ABCB1 transporter both in vitro and in vivo</article-title><source>Acta Pharm Sin B</source><year>2019</year><volume>9</volume><issue>2</issue><fpage>316</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2018.10.001</pub-id><?supplied-pmid 30972279?><pub-id pub-id-type="pmid">30972279</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>QE</given-names></name><name><surname>Li</surname><given-names>HD</given-names></name><name><surname>Yan</surname><given-names>M</given-names></name><name><surname>Cai</surname><given-names>HL</given-names></name><name><surname>Tan</surname><given-names>QY</given-names></name><name><surname>Zhang</surname><given-names>WY</given-names></name></person-group><article-title>Astragalus polysaccharides can regulate cytokine and P-glycoprotein expression in H22 tumor-bearing mice</article-title><source>World J Gastroenterol</source><year>2012</year><volume>18</volume><issue>47</issue><fpage>7079</fpage><lpage>7086</lpage><pub-id pub-id-type="doi">10.3748/wjg.v18.i47.7079</pub-id><?supplied-pmid 23323011?><pub-id pub-id-type="pmid">23323011</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>R</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name></person-group><article-title>Rosmarinic acid combined with adriamycin induces apoptosis by triggering mitochondria-mediated signaling pathway in hepG2 and bel-7402 cells</article-title><source>Med Sci Monit</source><year>2018</year><volume>24</volume><fpage>7898</fpage><lpage>7908</lpage><pub-id pub-id-type="doi">10.12659/msm.910673</pub-id><?supplied-pmid 30391993?><pub-id pub-id-type="pmid">30391993</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>Inagaki</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Qi</surname><given-names>F</given-names></name><name><surname>Song</surname><given-names>P</given-names></name><name><surname>Han</surname><given-names>G</given-names></name><name><surname>Sawakami</surname><given-names>T</given-names></name><name><surname>Gao</surname><given-names>B</given-names></name><name><surname>Luo</surname><given-names>C</given-names></name><name><surname>Kokudo</surname><given-names>N</given-names></name><name><surname>Hasegawa</surname><given-names>K</given-names></name><name><surname>Sakamoto</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name></person-group><article-title>Combination of cinobufacini and doxorubicin increases apoptosis of hepatocellular carcinoma cells through the fas- and mitochondria-mediated pathways</article-title><source>A J Chinese Med</source><year>2017</year><volume>45</volume><issue>7</issue><fpage>1537</fpage><lpage>1556</lpage><pub-id pub-id-type="doi">10.1142/s0192415x17500835</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Dong</surname><given-names>Q</given-names></name></person-group><article-title>Quercetin potentiates doxorubicin mediated antitumor effects against liver cancer through p53/Bcl-xl</article-title><source>PLoS One</source><year>2012</year><pub-id pub-id-type="doi">10.1371/journal.pone.0051764</pub-id><?supplied-pmid 23308088?><pub-id pub-id-type="pmid">23308088</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Cai</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name></person-group><article-title>Dahuang Zhechong Pill combined with doxorubicin induces cell death through regulating energy metabolism in human hepatocellular carcinoma cells</article-title><source>Evid Based Complement Alternat Med</source><year>2017</year><volume>2017</volume><fpage>6279576</fpage><pub-id pub-id-type="doi">10.1155/2017/6279576</pub-id><?supplied-pmid 28785292?><pub-id pub-id-type="pmid">28785292</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Cao</surname><given-names>KX</given-names></name><name><surname>Ni</surname><given-names>ZH</given-names></name><name><surname>Li</surname><given-names>WD</given-names></name><name><surname>Chen</surname><given-names>ZP</given-names></name><name><surname>Cheng</surname><given-names>HB</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name></person-group><article-title>Effects of Dahuang zhechong pill on doxorubicin-resistant SMMC-7721 xenografts in mice</article-title><source>J Ethnopharmacol</source><year>2018</year><volume>222</volume><fpage>71</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2018.03.039</pub-id><?supplied-pmid 29609009?><pub-id pub-id-type="pmid">29609009</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>TL</given-names></name><name><surname>Zhang</surname><given-names>LN</given-names></name><name><surname>Gu</surname><given-names>YY</given-names></name><name><surname>Lin</surname><given-names>MG</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>YL</given-names></name><name><surname>Liu</surname><given-names>JH</given-names></name><name><surname>Wu</surname><given-names>XL</given-names></name><name><surname>Mo</surname><given-names>SL</given-names></name></person-group><article-title>The synergistic antitumor effect of tanshinone iia plus adriamycin on human hepatocellular carcinoma xenograft in BALB/C nude mice and their influences on cytochrome P450 CYP3A4 in vivo</article-title><source>Adv Med</source><year>2020</year><volume>2020</volume><fpage>6231751</fpage><pub-id pub-id-type="doi">10.1155/2020/6231751</pub-id><?supplied-pmid 34189145?><pub-id pub-id-type="pmid">34189145</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Tie</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Bi</surname><given-names>F</given-names></name></person-group><article-title>Tanshinone II improves distribution and anti-tumor efficacy of pegylated liposomal doxorubicin via normalizing the structure and function of tumor vasculature in hepa1-6 hepatoma mice model</article-title><source>J Tradit Chin Med</source><year>2018</year><volume>38</volume><issue>6</issue><fpage>815</fpage><lpage>822</lpage><pub-id pub-id-type="doi">10.1016/S0254-6272(18)30980-4</pub-id><pub-id pub-id-type="pmid">32186128</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>H</given-names></name><name><surname>Jin</surname><given-names>Z</given-names></name><name><surname>Qian</surname><given-names>T</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Fei</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Sui</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name></person-group><article-title>Falcarindiol enhances cisplatin chemosensitivity of hepatocellular carcinoma via down-regulating the STAT3-modulated PTTG1 Pathway</article-title><source>Front Pharmacol</source><year>2021</year><volume>12</volume><fpage>656697</fpage><pub-id pub-id-type="doi">10.3389/fphar.2021.656697</pub-id><?supplied-pmid 34025420?><pub-id pub-id-type="pmid">34025420</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qu</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Zhai</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Tao</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>T</given-names></name></person-group><article-title>Astragaloside IV enhances cisplatin chemosensitivity in hepatocellular carcinoma by suppressing MRP2</article-title><source>Eur J Pharm Sci</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.ejps.2020.105325</pub-id><?supplied-pmid 33065226?><pub-id pub-id-type="pmid">33065226</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>G</given-names></name><name><surname>Cao</surname><given-names>C</given-names></name><name><surname>Deng</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Cen</surname><given-names>C</given-names></name></person-group><article-title>Effects of matrine in combination with cisplatin on liver cancer</article-title><source>Oncol Lett</source><year>2021</year><volume>21</volume><issue>1</issue><fpage>66</fpage><pub-id pub-id-type="doi">10.3892/ol.2020.12327</pub-id><?supplied-pmid 33365077?><pub-id pub-id-type="pmid">33365077</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>QH</given-names></name><name><surname>Meng</surname><given-names>H</given-names></name><name><surname>Zhong</surname><given-names>AP</given-names></name></person-group><article-title>Antitumor and synergistic effect of Chinese medicine "bushen huayu jiedu recipe" and chemotherapy on transplanted animal hepatocarcinoma</article-title><source>World J Gastroenterol</source><year>2005</year><volume>11</volume><issue>33</issue><fpage>5218</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.3748/wjg.v11.i33.5218</pub-id><?supplied-pmid 16127756?><pub-id pub-id-type="pmid">16127756</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tai</surname><given-names>CJ</given-names></name><name><surname>Wang</surname><given-names>WC</given-names></name><name><surname>Wang</surname><given-names>CK</given-names></name><name><surname>Wu</surname><given-names>CH</given-names></name><name><surname>Yang</surname><given-names>MD</given-names></name><name><surname>Chang</surname><given-names>YJ</given-names></name><name><surname>Jian</surname><given-names>JY</given-names></name><name><surname>Tai</surname><given-names>CJ</given-names></name></person-group><article-title>Fermented wheat germ extract induced cell death and enhanced cytotoxicity of Cisplatin and 5-Fluorouracil on human hepatocellular carcinoma cells</article-title><source>Evid Based Complement Alternat Med</source><year>2013</year><volume>2013</volume><fpage>121725</fpage><pub-id pub-id-type="doi">10.1155/2013/121725</pub-id><?supplied-pmid 24454483?><pub-id pub-id-type="pmid">24454483</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Yin</surname><given-names>M</given-names></name><name><surname>Pan</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>Q</given-names></name><name><surname>Zhu</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Ding</surname><given-names>B</given-names></name><name><surname>Ji</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name></person-group><article-title>Solanum nigrum polysaccharide inhibits tumor growth in H22-bearing mice through regulation of caspase-3 and bcl-2</article-title><source>J Cancer Res Ther</source><year>2018</year><volume>14</volume><issue>Supplement</issue><fpage>S232</fpage><lpage>s236</lpage><pub-id pub-id-type="doi">10.4103/0973-1482.206862</pub-id><?supplied-pmid 29578179?><pub-id pub-id-type="pmid">29578179</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>CK</given-names></name><name><surname>Lin</surname><given-names>YF</given-names></name><name><surname>Tai</surname><given-names>CJ</given-names></name><name><surname>Wang</surname><given-names>CW</given-names></name><name><surname>Chang</surname><given-names>YJ</given-names></name><name><surname>Choong</surname><given-names>CY</given-names></name><name><surname>Lin</surname><given-names>CS</given-names></name><name><surname>Tai</surname><given-names>CJ</given-names></name><name><surname>Chang</surname><given-names>CC</given-names></name></person-group><article-title>Integrated treatment of aqueous extract of solanum nigrum-potentiated cisplatin- and doxorubicin-induced cytotoxicity in human hepatocellular carcinoma cells</article-title><source>Evid Based Complement Alternat Med</source><year>2015</year><volume>2015</volume><fpage>675270</fpage><pub-id pub-id-type="doi">10.1155/2015/675270</pub-id><?supplied-pmid 26221175?><pub-id pub-id-type="pmid">26221175</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stordal</surname><given-names>B</given-names></name><name><surname>Pavlakis</surname><given-names>N</given-names></name><name><surname>Davey</surname><given-names>R</given-names></name></person-group><article-title>Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review</article-title><source>Cancer Treat Rev</source><year>2007</year><volume>33</volume><issue>4</issue><fpage>347</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2007.01.009</pub-id><?supplied-pmid 17383100?><pub-id pub-id-type="pmid">17383100</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>F</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name></person-group><article-title>Polysaccharide from Lentinus edodes combined with oxaliplatin possesses the synergy and attenuation effect in hepatocellular carcinoma</article-title><source>Cancer Letters</source><year>2016</year><volume>377</volume><issue>2</issue><fpage>117</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2016.04.037</pub-id><?supplied-pmid 27130669?><pub-id pub-id-type="pmid">27130669</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname><given-names>Y</given-names></name><name><surname>Shan</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Qian</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Liang</surname><given-names>B</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Cai</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name></person-group><article-title>Huaier augmented the chemotherapeutic sensitivity of oxaliplatin via downregulation of YAP in hepatocellular carcinoma</article-title><source>J Cancer</source><year>2018</year><volume>9</volume><issue>21</issue><fpage>3962</fpage><lpage>3970</lpage><pub-id pub-id-type="doi">10.7150/jca.25909</pub-id><?supplied-pmid 30410600?><pub-id pub-id-type="pmid">30410600</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>To</surname><given-names>KK</given-names></name><name><surname>Ho</surname><given-names>YP</given-names></name><name><surname>Au-Yeung</surname><given-names>SC</given-names></name></person-group><article-title>Synergistic interaction between platinum-based antitumor agents and demethylcantharidin</article-title><source>Cancer Lett</source><year>2005</year><volume>223</volume><issue>2</issue><fpage>227</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2004.10.036</pub-id><?supplied-pmid 15896457?><pub-id pub-id-type="pmid">15896457</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X-Y</given-names></name><name><surname>Zhou</surname><given-names>F</given-names></name><name><surname>Cai</surname><given-names>Y-J</given-names></name><name><surname>Sun</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>R-P</given-names></name></person-group><article-title>Ziyuglycoside II inhibits the growth of digestive system cancer cells through multiple mechanisms</article-title><source>Chinese J Nat Med</source><year>2021</year><volume>19</volume><issue>5</issue><fpage>351</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1016/s1875-5364(21)60033-x</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>XF</given-names></name><name><surname>Li</surname><given-names>XJ</given-names></name><name><surname>Cao</surname><given-names>ZL</given-names></name><name><surname>Liu</surname><given-names>XJ</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Ju</surname><given-names>D</given-names></name><name><surname>Mu</surname><given-names>Q</given-names></name></person-group><article-title>Synergistic antitumor effect of 5-fluorouracil combined with constituents from pleurospermum lindleyanum in hepatocellular carcinoma SMMC-7721 cells</article-title><source>Anticancer Agents Med Chem</source><year>2021</year><volume>21</volume><issue>4</issue><fpage>508</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.2174/1871520620666200824094624</pub-id><?supplied-pmid 32838723?><pub-id pub-id-type="pmid">32838723</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>FQ</given-names></name><name><surname>Li</surname><given-names>SP</given-names></name><name><surname>Gao</surname><given-names>JL</given-names></name><name><surname>Hu</surname><given-names>G</given-names></name><name><surname>Lao</surname><given-names>SC</given-names></name><name><surname>Concei&#x000e7;&#x000e3;o</surname><given-names>EL</given-names></name><name><surname>Fung</surname><given-names>KP</given-names></name><name><surname>Wangl</surname><given-names>YT</given-names></name><name><surname>Lee</surname><given-names>SM</given-names></name></person-group><article-title>Furanodiene induces G2/M cell cycle arrest and apoptosis through MAPK signaling and mitochondria-caspase pathway in human hepatocellular carcinoma cells</article-title><source>Cancer Biol Ther</source><year>2007</year><volume>6</volume><issue>7</issue><fpage>1044</fpage><lpage>1050</lpage><pub-id pub-id-type="doi">10.4161/cbt.6.7.4317</pub-id><?supplied-pmid 17611410?><pub-id pub-id-type="pmid">17611410</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>X-Y</given-names></name><name><surname>Guo</surname><given-names>D-W</given-names></name><name><surname>Lao</surname><given-names>Q-C</given-names></name><name><surname>Xu</surname><given-names>Y-Q</given-names></name><name><surname>Meng</surname><given-names>Z-K</given-names></name><name><surname>Xia</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>C-Q</given-names></name><name><surname>Li</surname><given-names>P</given-names></name></person-group><article-title>Sensitization and synergistic anti-cancer effects of Furanodiene identified in zebrafish models</article-title><source>Sci Rep</source><year>2019</year><pub-id pub-id-type="doi">10.1038/s41598-019-40866-2</pub-id><?supplied-pmid 31892720?><pub-id pub-id-type="pmid">31892720</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xi</surname><given-names>S</given-names></name><name><surname>Zhai</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>B</given-names></name><name><surname>Gao</surname><given-names>C</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>D</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Qian</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>The Ciji-Hua'ai-Baosheng II formula attenuates chemotherapy-induced anorexia in mice with h(22) hepatocellular carcinoma</article-title><source>Front Pharmacol</source><year>2021</year><volume>12</volume><fpage>715824</fpage><pub-id pub-id-type="doi">10.3389/fphar.2021.715824</pub-id><?supplied-pmid 34489705?><pub-id pub-id-type="pmid">34489705</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>M</given-names></name><name><surname>Kong</surname><given-names>L</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name></person-group><article-title>Gut microbiota enhances the chemosensitivity of hepatocellular carcinoma to 5-fluorouracil in vivo by increasing curcumin bioavailability</article-title><source>Phytother Res</source><year>2021</year><pub-id pub-id-type="doi">10.1002/ptr.7240</pub-id><?supplied-pmid 34962325?><pub-id pub-id-type="pmid">34962325</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>CP</given-names></name><name><surname>Ding</surname><given-names>HX</given-names></name><name><surname>Liu</surname><given-names>YX</given-names></name><name><surname>Di</surname><given-names>QF</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>GX</given-names></name></person-group><article-title>Water-soluble total flavonoids isolated from isodon lophanthoides var gerardianus (benth) h hara promote hepatocellular carcinoma sensitivity to 5-fluorouracil</article-title><source>Evid Based Complement Alternat Med</source><year>2021</year><pub-id pub-id-type="doi">10.1155/2021/6623212</pub-id><?supplied-pmid 35003312?><pub-id pub-id-type="pmid">35003312</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Wei</surname><given-names>N</given-names></name></person-group><article-title>H1, a derivative of tetrandrine, enhances the efficacy of 5-FU in Bel7402/5-FU cells via suppressing STAT3/MCL-1 and inducing PUMA</article-title><source>Biochem Biophys Res Commun</source><year>2019</year><volume>520</volume><issue>1</issue><fpage>93</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2019.09.082</pub-id><?supplied-pmid 31582208?><pub-id pub-id-type="pmid">31582208</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>Z</given-names></name><name><surname>Ma</surname><given-names>K</given-names></name><name><surname>Dong</surname><given-names>B</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Che</surname><given-names>C</given-names></name><name><surname>Dong</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Liang</surname><given-names>R</given-names></name></person-group><article-title>The synergistic antitumor effect of Huaier combined with 5-Florouracil in human cholangiocarcinoma cells</article-title><source>Bmc Complement Alter Med</source><year>2019</year><pub-id pub-id-type="doi">10.1186/s12906-019-2614-5</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>YP</given-names></name><name><surname>Yang</surname><given-names>ZR</given-names></name><name><surname>Guo</surname><given-names>XF</given-names></name><name><surname>Jun</surname><given-names>W</given-names></name><name><surname>Dong</surname><given-names>WG</given-names></name></person-group><article-title>Synergistic effect of puerarin and 5-fluorouracil on hepatocellular carcinoma</article-title><source>Oncol Lett</source><year>2014</year><volume>8</volume><issue>6</issue><fpage>2436</fpage><lpage>2442</lpage><pub-id pub-id-type="doi">10.3892/ol.2014.2534</pub-id><?supplied-pmid 25364405?><pub-id pub-id-type="pmid">25364405</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Yuan</surname><given-names>R</given-names></name><name><surname>Su</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Du</surname><given-names>G</given-names></name></person-group><article-title>Luteolin synergizes the antitumor effects of 5-fluorouracil against human hepatocellular carcinoma cells through apoptosis induction and metabolism</article-title><source>Life Sci</source><year>2016</year><volume>144</volume><fpage>138</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2015.12.002</pub-id><?supplied-pmid 26656468?><pub-id pub-id-type="pmid">26656468</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>ZJ</given-names></name><name><surname>Pan</surname><given-names>CE</given-names></name><name><surname>Liu</surname><given-names>HS</given-names></name><name><surname>Wang</surname><given-names>GJ</given-names></name></person-group><article-title>Anti-hepatoma activity of resveratrol in vitro</article-title><source>World J Gastroenterol</source><year>2002</year><volume>8</volume><issue>1</issue><fpage>79</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.3748/wjg.v8.i1.79</pub-id><?supplied-pmid 11833076?><pub-id pub-id-type="pmid">11833076</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>SL</given-names></name><name><surname>Sun</surname><given-names>ZJ</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Meng</surname><given-names>KW</given-names></name><name><surname>Qin</surname><given-names>XL</given-names></name><name><surname>Pan</surname><given-names>CE</given-names></name></person-group><article-title>Effect of resveratrol and in combination with 5-FU on murine liver cancer</article-title><source>World J Gastroenterol</source><year>2004</year><volume>10</volume><issue>20</issue><fpage>3048</fpage><lpage>3052</lpage><pub-id pub-id-type="doi">10.3748/wjg.v10.i20.3048</pub-id><?supplied-pmid 15378791?><pub-id pub-id-type="pmid">15378791</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Que</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Fu</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Xia</surname><given-names>X</given-names></name><name><surname>Lv</surname><given-names>J</given-names></name><name><surname>Du</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Zhong</surname><given-names>Y</given-names></name></person-group><article-title>Herbal formula of bushen Jianpi combined with sorafenib inhibits hepatocellular carcinoma growth by promoting cell apoptosis and blocking the cell cycle</article-title><source>J Tradit Chin Med</source><year>2021</year><volume>41</volume><issue>2</issue><fpage>194</fpage><lpage>202</lpage><?supplied-pmid 33825398?><pub-id pub-id-type="pmid">33825398</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Bai</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Yan</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Shi</surname><given-names>M</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name></person-group><article-title>Sorafenib and CuB exert synergistic antitumor effects against hepatocellular carcinoma cells via inhibition of STAT3 phosphorylation</article-title><source>FEBS Open Bio</source><year>2021</year><volume>11</volume><issue>1</issue><fpage>133</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1002/2211-5463.13035</pub-id><?supplied-pmid 33176070?><pub-id pub-id-type="pmid">33176070</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Chi</surname><given-names>H</given-names></name><name><surname>Meng</surname><given-names>Z</given-names></name></person-group><article-title>Synergistic anticancer effects of bufalin and sorafenib by regulating apoptosis associated proteins</article-title><source>Mol Med Rep</source><year>2018</year><volume>17</volume><issue>6</issue><fpage>8101</fpage><lpage>8110</lpage><pub-id pub-id-type="doi">10.3892/mmr.2018.8927</pub-id><?supplied-pmid 29693132?><pub-id pub-id-type="pmid">29693132</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Chi</surname><given-names>H</given-names></name><name><surname>Meng</surname><given-names>Z</given-names></name></person-group><article-title>Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling</article-title><source>Int J Oncol</source><year>2018</year><volume>52</volume><issue>6</issue><fpage>2051</fpage><lpage>2060</lpage><pub-id pub-id-type="doi">10.3892/ijo.2018.4351</pub-id><?supplied-pmid 29620259?><pub-id pub-id-type="pmid">29620259</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Feng</surname><given-names>H</given-names></name><name><surname>Zhuo</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Zheng</surname><given-names>C</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Le</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>DY</given-names></name><name><surname>Cheng</surname><given-names>AS</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name></person-group><article-title>Bufalin inhibits hepatitis B virus-associated hepatocellular carcinoma development through androgen receptor dephosphorylation and cell cycle-related kinase degradation</article-title><source>Cell Oncol</source><year>2020</year><volume>43</volume><issue>6</issue><fpage>1129</fpage><lpage>1145</lpage><pub-id pub-id-type="doi">10.1007/s13402-020-00546-0</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>SS</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Kong</surname><given-names>LC</given-names></name><name><surname>Wei</surname><given-names>P</given-names></name></person-group><article-title>Celastrol enhances the antiliver cancer activity of sorafenib</article-title><source>Med Sci Monit.</source><year>2019</year><volume>25</volume><fpage>4068</fpage><lpage>4075</lpage><pub-id pub-id-type="doi">10.12659/msm.914060</pub-id><?supplied-pmid 31152143?><pub-id pub-id-type="pmid">31152143</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Man</surname><given-names>S</given-names></name><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Lv</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name></person-group><article-title>Curcumin-enhanced antitumor effects of sorafenib via regulating the metabolism and tumor microenvironment</article-title><source>Food Function</source><year>2020</year><volume>11</volume><issue>7</issue><fpage>6422</fpage><lpage>6432</lpage><pub-id pub-id-type="doi">10.1039/c9fo01901d</pub-id><?supplied-pmid 32613952?><pub-id pub-id-type="pmid">32613952</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name></person-group><article-title>Oridonin sensitizes hepatocellular carcinoma to the anticancer effect of sorafenib by targeting the Akt pathway</article-title><source>Cancer Manag Res</source><year>2020</year><volume>12</volume><fpage>8081</fpage><lpage>8091</lpage><pub-id pub-id-type="doi">10.2147/cmar.S257482</pub-id><?supplied-pmid 32982405?><pub-id pub-id-type="pmid">32982405</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>JH</given-names></name><name><surname>Chiang</surname><given-names>IT</given-names></name><name><surname>Hsu</surname><given-names>FT</given-names></name></person-group><article-title>Protein kinase B inactivation is associated with magnolol-enhanced therapeutic efficacy of sorafenib in hepatocellular carcinoma in vitro and in vivo</article-title><source>Cancers</source><year>2019</year><pub-id pub-id-type="doi">10.3390/cancers12010087</pub-id><?supplied-pmid 31906029?><pub-id pub-id-type="pmid">31906029</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>MH</given-names></name><name><surname>Chiu</surname><given-names>YF</given-names></name><name><surname>Wu</surname><given-names>WJ</given-names></name><name><surname>Wu</surname><given-names>PL</given-names></name><name><surname>Lin</surname><given-names>CY</given-names></name><name><surname>Lin</surname><given-names>CL</given-names></name><name><surname>Hsieh</surname><given-names>YH</given-names></name><name><surname>Liu</surname><given-names>CJ</given-names></name></person-group><article-title>Synergistic antimetastatic effect of cotreatment with licochalcone A and sorafenib on human hepatocellular carcinoma cells through the inactivation of MKK4/JNK and uPA expression</article-title><source>Environ Toxicol</source><year>2018</year><volume>33</volume><issue>12</issue><fpage>1237</fpage><lpage>1244</lpage><pub-id pub-id-type="doi">10.1002/tox.22630</pub-id><?supplied-pmid 30187994?><pub-id pub-id-type="pmid">30187994</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>M</given-names></name><name><surname>Yao</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>Z</given-names></name><name><surname>Qiu</surname><given-names>L</given-names></name><name><surname>You</surname><given-names>R</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Ba</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name></person-group><article-title>Compound kushen injection relieves tumor-associated macrophage mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib</article-title><source>J Immunother Cancer</source><year>2020</year><pub-id pub-id-type="doi">10.1136/jitc-2019-000317</pub-id><?supplied-pmid 33427691?><pub-id pub-id-type="pmid">33427691</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Hua</surname><given-names>H</given-names></name><name><surname>Kong</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name></person-group><article-title>Targeting Na(+) /K(+) -ATPase by berbamine and ouabain synergizes with sorafenib to inhibit hepatocellular carcinoma</article-title><source>Br J Pharmacol</source><year>2021</year><pub-id pub-id-type="doi">10.1111/bph.15616</pub-id><?supplied-pmid 34796475?><pub-id pub-id-type="pmid">34796475</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>CY</given-names></name><name><surname>Chen</surname><given-names>CC</given-names></name><name><surname>Chuang</surname><given-names>WY</given-names></name><name><surname>Leu</surname><given-names>YL</given-names></name><name><surname>Ueng</surname><given-names>SH</given-names></name><name><surname>Hsueh</surname><given-names>C</given-names></name><name><surname>Yeh</surname><given-names>CT</given-names></name><name><surname>Wang</surname><given-names>TH</given-names></name></person-group><article-title>Hydroxygenkwanin Inhibits class I HDAC expression and synergistically enhances the antitumor activity of sorafenib in liver cancer cells</article-title><source>Front Oncol</source><year>2020</year><volume>10</volume><fpage>216</fpage><pub-id pub-id-type="doi">10.3389/fonc.2020.00216</pub-id><?supplied-pmid 32158695?><pub-id pub-id-type="pmid">32158695</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>ZJ</given-names></name><name><surname>Dai</surname><given-names>HQ</given-names></name><name><surname>Huang</surname><given-names>XW</given-names></name><name><surname>Feng</surname><given-names>J</given-names></name><name><surname>Deng</surname><given-names>JH</given-names></name><name><surname>Wang</surname><given-names>ZX</given-names></name><name><surname>Yang</surname><given-names>XM</given-names></name><name><surname>Liu</surname><given-names>YJ</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>PH</given-names></name><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>JG</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>GD</given-names></name></person-group><article-title>Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma</article-title><source>Acta Pharmacol Sin</source><year>2021</year><volume>42</volume><issue>2</issue><fpage>301</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1038/s41401-020-0478-3</pub-id><?supplied-pmid 32699265?><pub-id pub-id-type="pmid">32699265</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Lam</surname><given-names>W</given-names></name><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Guan</surname><given-names>F</given-names></name><name><surname>Han</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>R</given-names></name><name><surname>Cai</surname><given-names>W</given-names></name><name><surname>Cheng</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>SH</given-names></name><name><surname>Cheng</surname><given-names>P</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Rattray</surname><given-names>NJW</given-names></name><name><surname>Johnson</surname><given-names>CH</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Cheng</surname><given-names>YC</given-names></name></person-group><article-title>YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate immunity in the tumor microenvironment</article-title><source>Sci Rep</source><year>2021</year><volume>11</volume><issue>1</issue><fpage>13482</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-91623-3</pub-id><?supplied-pmid 34188068?><pub-id pub-id-type="pmid">34188068</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>Trivett</surname><given-names>AL</given-names></name><name><surname>Hannifin</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Oppenheim</surname><given-names>JJ</given-names></name></person-group><article-title>Inhibition of murine hepatoma tumor growth by cryptotanshinone involves TLR7-dependent activation of macrophages and induction of adaptive antitumor immune defenses</article-title><source>Cancer Immunol Immunother</source><year>2019</year><volume>68</volume><issue>7</issue><fpage>1073</fpage><lpage>1085</lpage><pub-id pub-id-type="doi">10.1007/s00262-019-02338-4</pub-id><?supplied-pmid 31161238?><pub-id pub-id-type="pmid">31161238</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Man</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>P</given-names></name><name><surname>Gao</surname><given-names>W</given-names></name></person-group><article-title>Combination treatment with Rhizoma paridis and rhizoma curcuma longa extracts and 10-hydroxycamptothecin enhances the antitumor effect in h22 tumor model by increasing the plasma concentration</article-title><source>Biomed Pharmacother</source><year>2016</year><volume>83</volume><fpage>627</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2016.07.026</pub-id><?supplied-pmid 27459119?><pub-id pub-id-type="pmid">27459119</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Qu</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name></person-group><article-title>Resveratrol enhances anticancer effects of paclitaxel in HepG2 human liver cancer cells</article-title><source>BMC Complement Altern Med</source><year>2017</year><volume>17</volume><issue>1</issue><fpage>477</fpage><pub-id pub-id-type="doi">10.1186/s12906-017-1956-0</pub-id><?supplied-pmid 28978315?><pub-id pub-id-type="pmid">28978315</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>N</given-names></name><name><surname>Yan</surname><given-names>A</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Mi</surname><given-names>M</given-names></name><name><surname>Tang</surname><given-names>X</given-names></name><name><surname>Gou</surname><given-names>X</given-names></name></person-group><article-title>Berberine sensitizes rapamycin-mediated human hepatoma cell death in vitro</article-title><source>Mol Med Rep</source><year>2014</year><volume>10</volume><issue>6</issue><fpage>3132</fpage><lpage>3138</lpage><pub-id pub-id-type="doi">10.3892/mmr.2014.2608</pub-id><?supplied-pmid 25310356?><pub-id pub-id-type="pmid">25310356</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Hu</surname><given-names>C</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Cai</surname><given-names>X</given-names></name></person-group><article-title>Elemene injection induced autophagy protects human hepatoma cancer cells from starvation and undergoing apoptosis</article-title><source>Evidence Based Complement Alter Med</source><year>2014</year><pub-id pub-id-type="doi">10.1155/2014/637528</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bukowski</surname><given-names>K</given-names></name><name><surname>Kciuk</surname><given-names>M</given-names></name><name><surname>Kontek</surname><given-names>R</given-names></name></person-group><article-title>Mechanisms of multidrug resistance in cancer chemotherapy</article-title><source>Int J Mol Sci</source><year>2020</year><pub-id pub-id-type="doi">10.3390/ijms21093233</pub-id><?supplied-pmid 33105833?><pub-id pub-id-type="pmid">33105833</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Q</given-names></name><name><surname>Cao</surname><given-names>H</given-names></name><name><surname>Qi</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Ye</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Sun</surname><given-names>M</given-names></name></person-group><article-title>Research progress in reversal of tumor multi-drug resistance via natural products</article-title><source>Anticancer Agents Med Chem</source><year>2017</year><volume>17</volume><issue>11</issue><fpage>1466</fpage><lpage>1476</lpage><pub-id pub-id-type="doi">10.2174/1871520617666171016105704</pub-id><?supplied-pmid 29034843?><pub-id pub-id-type="pmid">29034843</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>LH</given-names></name><name><surname>Bao</surname><given-names>YL</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>CL</given-names></name><name><surname>Meng</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>YX</given-names></name></person-group><article-title>Cantharidin reverses multidrug resistance of human hepatoma HepG2/ADM cells via down-regulation of P-glycoprotein expression</article-title><source>Cancer Lett</source><year>2008</year><volume>272</volume><issue>1</issue><fpage>102</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2008.06.029</pub-id><?supplied-pmid 18703276?><pub-id pub-id-type="pmid">18703276</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name></person-group><article-title>Gambogenic acid reverses P-glycoprotein mediated multidrug resistance in HepG2/Adr cells and its underlying mechanism</article-title><source>Biochem Biophys Res Commun</source><year>2019</year><volume>508</volume><issue>3</issue><fpage>882</fpage><lpage>888</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2018.12.028</pub-id><?supplied-pmid 30538042?><pub-id pub-id-type="pmid">30538042</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>JY</given-names></name><name><surname>Chan</surname><given-names>MK</given-names></name><name><surname>Tang</surname><given-names>PC</given-names></name><name><surname>Chan</surname><given-names>AS</given-names></name><name><surname>Chung</surname><given-names>JS</given-names></name><name><surname>Meng</surname><given-names>XM</given-names></name><name><surname>To</surname><given-names>KF</given-names></name><name><surname>Lan</surname><given-names>HY</given-names></name><name><surname>Leung</surname><given-names>KT</given-names></name><name><surname>Tang</surname><given-names>PM</given-names></name></person-group><article-title>AANG: A natural compound formula for overcoming multidrug resistance via synergistic rebalancing the TGF-&#x003b2;/Smad signalling in hepatocellular carcinoma</article-title><source>J Cell Mol Med</source><year>2021</year><volume>25</volume><issue>20</issue><fpage>9805</fpage><lpage>9813</lpage><pub-id pub-id-type="doi">10.1111/jcmm.16928</pub-id><?supplied-pmid 34514726?><pub-id pub-id-type="pmid">34514726</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Luo</surname><given-names>Z</given-names></name><name><surname>Mao</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Fei</surname><given-names>Y</given-names></name><name><surname>Pei</surname><given-names>Y</given-names></name><name><surname>Cai</surname><given-names>K</given-names></name></person-group><article-title>Overcoming the hypoxia-induced drug resistance in liver tumor by the concurrent use of apigenin and paclitaxel</article-title><source>Biochem Biophys Res Commun</source><year>2020</year><volume>526</volume><issue>2</issue><fpage>321</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2020.03.010</pub-id><?supplied-pmid 32220496?><pub-id pub-id-type="pmid">32220496</pub-id></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>WC</given-names></name><name><surname>Ramesh</surname><given-names>S</given-names></name><name><surname>Shibu</surname><given-names>MA</given-names></name><name><surname>Chen</surname><given-names>MC</given-names></name><name><surname>Wang</surname><given-names>TF</given-names></name><name><surname>Day</surname><given-names>CH</given-names></name><name><surname>Chen</surname><given-names>RJ</given-names></name><name><surname>Padma</surname><given-names>VV</given-names></name><name><surname>Li</surname><given-names>CC</given-names></name><name><surname>Tseng</surname><given-names>YC</given-names></name><name><surname>Huang</surname><given-names>CY</given-names></name></person-group><article-title>Platycodin D reverses histone deacetylase inhibitor resistance in hepatocellular carcinoma cells by repressing ERK1/2-mediated cofilin-1 phosphorylation</article-title><source>Phytomedicine</source><year>2021</year><volume>82</volume><fpage>153442</fpage><pub-id pub-id-type="doi">10.1016/j.phymed.2020.153442</pub-id><?supplied-pmid 33412494?><pub-id pub-id-type="pmid">33412494</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orcutt</surname><given-names>ST</given-names></name><name><surname>Anaya</surname><given-names>DA</given-names></name></person-group><article-title>Liver resection and surgical strategies for management of primary liver cancer</article-title><source>Cancer Control</source><year>2018</year><pub-id pub-id-type="doi">10.1177/1073274817744621</pub-id><?supplied-pmid 29327594?><pub-id pub-id-type="pmid">29327594</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Padhya</surname><given-names>KT</given-names></name><name><surname>Marrero</surname><given-names>JA</given-names></name><name><surname>Singal</surname><given-names>AG</given-names></name></person-group><article-title>Recent advances in the treatment of hepatocellular carcinoma</article-title><source>Curr Opin Gastroenterol</source><year>2013</year><volume>29</volume><issue>3</issue><fpage>285</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1097/MOG.0b013e32835ff1cf</pub-id><?supplied-pmid 23507917?><pub-id pub-id-type="pmid">23507917</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhai</surname><given-names>XF</given-names></name><name><surname>Liu</surname><given-names>XL</given-names></name><name><surname>Shen</surname><given-names>F</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Ling</surname><given-names>CQ</given-names></name></person-group><article-title>Traditional herbal medicine prevents postoperative recurrence of small hepatocellular carcinoma: a randomized controlled study</article-title><source>Cancer</source><year>2018</year><volume>124</volume><issue>10</issue><fpage>2161</fpage><lpage>2168</lpage><pub-id pub-id-type="doi">10.1002/cncr.30915</pub-id><?supplied-pmid 29499082?><pub-id pub-id-type="pmid">29499082</pub-id></element-citation></ref><ref id="CR124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Shu</surname><given-names>C</given-names></name><name><surname>Laurence</surname><given-names>AD</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Peng</surname><given-names>BG</given-names></name><name><surname>Zhen</surname><given-names>ZJ</given-names></name><name><surname>Cai</surname><given-names>JQ</given-names></name><name><surname>Ding</surname><given-names>YT</given-names></name><name><surname>Li</surname><given-names>LQ</given-names></name><name><surname>Zhang</surname><given-names>YB</given-names></name><name><surname>Zheng</surname><given-names>QC</given-names></name><name><surname>Xu</surname><given-names>GL</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Zhou</surname><given-names>WP</given-names></name><name><surname>Cai</surname><given-names>SW</given-names></name><name><surname>Wang</surname><given-names>XY</given-names></name><name><surname>Wen</surname><given-names>H</given-names></name><name><surname>Peng</surname><given-names>XY</given-names></name><name><surname>Zhang</surname><given-names>XW</given-names></name><name><surname>Dai</surname><given-names>CL</given-names></name><name><surname>Bie</surname><given-names>P</given-names></name><name><surname>Xing</surname><given-names>BC</given-names></name><name><surname>Fu</surname><given-names>ZR</given-names></name><name><surname>Liu</surname><given-names>LX</given-names></name><name><surname>Mu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>QS</given-names></name><name><surname>Jiang</surname><given-names>B</given-names></name><name><surname>Qian</surname><given-names>HX</given-names></name><name><surname>Wang</surname><given-names>YJ</given-names></name><name><surname>Liu</surname><given-names>JF</given-names></name><name><surname>Qin</surname><given-names>XH</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Yin</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>ZW</given-names></name><name><surname>Chen</surname><given-names>XP</given-names></name></person-group><article-title>Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial</article-title><source>Gut</source><year>2018</year><volume>67</volume><issue>11</issue><fpage>2006</fpage><lpage>2016</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2018-315983</pub-id><?supplied-pmid 29802174?><pub-id pub-id-type="pmid">29802174</pub-id></element-citation></ref><ref id="CR125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Ni</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Ling</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name></person-group><article-title>Erzhu qinggan jiedu recipe improves the clinical outcome of hepatocellular cancer after surgical resection: a case-control retrospective study</article-title><source>Intern Med J</source><year>2021</year><volume>51</volume><issue>6</issue><fpage>853</fpage><lpage>860</lpage><pub-id pub-id-type="doi">10.1111/imj.14844</pub-id><?supplied-pmid 32250022?><pub-id pub-id-type="pmid">32250022</pub-id></element-citation></ref><ref id="CR126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>HD</given-names></name><name><surname>Liu</surname><given-names>DY</given-names></name><name><surname>Xu</surname><given-names>FB</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>XM</given-names></name><name><surname>Guo</surname><given-names>RP</given-names></name></person-group><article-title>Clinical study of hepatectomy combined with Jianpi Huayu therapy for hepatocellular carcinoma</article-title><source>Asian Pac J Cancer Prev</source><year>2014</year><volume>15</volume><issue>14</issue><fpage>5951</fpage><lpage>5957</lpage><pub-id pub-id-type="doi">10.7314/apjcp.2014.15.14.5951</pub-id><?supplied-pmid 25081728?><pub-id pub-id-type="pmid">25081728</pub-id></element-citation></ref><ref id="CR127"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>CW</given-names></name><name><surname>Zhu</surname><given-names>M</given-names></name><name><surname>Feng</surname><given-names>WM</given-names></name><name><surname>Bao</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>YY</given-names></name></person-group><article-title>Chinese herbal medicine, Jianpi Ligan decoction, improves prognosis of unresectable hepatocellular carcinoma after transarterial chemoembolization: a retrospective study</article-title><source>Drug Des Dev Ther</source><year>2016</year><volume>10</volume><fpage>2461</fpage><lpage>2466</lpage><pub-id pub-id-type="doi">10.2147/dddt.S113295</pub-id></element-citation></ref><ref id="CR128"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>C</given-names></name><name><surname>Feng</surname><given-names>W</given-names></name><name><surname>Qin</surname><given-names>L</given-names></name><name><surname>Bao</surname><given-names>Y</given-names></name></person-group><article-title>Chinese herbal medicine, Jian Pi Li Gan decoction, improved survival of nonresectable hepatocellular cancer after radiofrequency ablation: a retrospective study</article-title><source>Integr Cancer Ther</source><year>2018</year><volume>17</volume><issue>2</issue><fpage>431</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1177/1534735417722223</pub-id><?supplied-pmid 28745082?><pub-id pub-id-type="pmid">28745082</pub-id></element-citation></ref><ref id="CR129"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>XL</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>ZG</given-names></name><name><surname>Han</surname><given-names>ZY</given-names></name><name><surname>Liu</surname><given-names>FY</given-names></name><name><surname>Dou</surname><given-names>JP</given-names></name><name><surname>Kong</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>XJ</given-names></name><name><surname>Zhao</surname><given-names>QX</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Liang</surname><given-names>P</given-names></name><name><surname>Tang</surname><given-names>WZ</given-names></name></person-group><article-title>Huaier granule prevents the recurrence of early-stage hepatocellular carcinoma after thermal ablation: a cohort study</article-title><source>J Ethnopharmacol.</source><year>2021</year><volume>281</volume><fpage>114539</fpage><pub-id pub-id-type="doi">10.1016/j.jep.2021.114539</pub-id><?supplied-pmid 34428522?><pub-id pub-id-type="pmid">34428522</pub-id></element-citation></ref><ref id="CR130"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Deng</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name></person-group><article-title>Chinese herbal medicine (Chaihu-Huaji Decoction) alleviates postembolization syndrome following transcatheter arterial chemoembolization and improves survival in unresectable hepatocellular cancer: a retrospective study</article-title><source>Evidence-Based Complement Altern Med</source><year>2019</year><volume>2019</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1155/2019/6269518</pub-id></element-citation></ref><ref id="CR131"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Ma</surname><given-names>Y-Z</given-names></name><name><surname>Song</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>C-H</given-names></name><name><surname>Qi</surname><given-names>T-G</given-names></name><name><surname>Shao</surname><given-names>G-R</given-names></name></person-group><article-title>Effect of cantharidins in chemotherapy for hepatoma: a retrospective cohort study</article-title><source>Am J Chinese Med</source><year>2014</year><volume>42</volume><issue>3</issue><fpage>561</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1142/s0192415x14500360</pub-id></element-citation></ref><ref id="CR132"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Liang</surname><given-names>ST</given-names></name><name><surname>Zhai</surname><given-names>XF</given-names></name><name><surname>Lang</surname><given-names>QB</given-names></name><name><surname>Zhou</surname><given-names>QH</given-names></name><name><surname>Yue</surname><given-names>XQ</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Ling</surname><given-names>CQ</given-names></name></person-group><article-title>A traditional Chinese herbal medicine compound preparation versus interventional therapy after resection of small hepatocellular carcinoma: 22-year follow-up</article-title><source>J Tradit Chin Med</source><year>2012</year><volume>32</volume><issue>2</issue><fpage>156</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1016/s0254-6272(13)60005-9</pub-id><?supplied-pmid 22876437?><pub-id pub-id-type="pmid">22876437</pub-id></element-citation></ref><ref id="CR133"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Yan</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Shi</surname><given-names>P</given-names></name><name><surname>Qian</surname><given-names>S</given-names></name><name><surname>Qu</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name></person-group><article-title>Prospective Study of Transcatheter Arterial Chemoembolization (TACE) with Ginsenoside Rg3 versus TACE Alone for the Treatment of Patients with Advanced Hepatocellular Carcinoma</article-title><source>Radiology.</source><year>2016</year><volume>280</volume><issue>2</issue><fpage>630</fpage><lpage>639</lpage><pub-id pub-id-type="doi">10.1148/radiol.2016150719</pub-id><?supplied-pmid 26885681?><pub-id pub-id-type="pmid">26885681</pub-id></element-citation></ref><ref id="CR134"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>GL</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>TY</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>GY</given-names></name><name><surname>Li</surname><given-names>JP</given-names></name></person-group><article-title>Short-term effect of combined therapy with Jinlong Capsule and transcatheter arterial chemoembolization on patients with primary hepatic carcinoma and its influence on serum osteopontin expression</article-title><source>Chin J Integr Med</source><year>2010</year><volume>16</volume><issue>2</issue><fpage>109</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1007/s11655-010-0109-9</pub-id><?supplied-pmid 20473734?><pub-id pub-id-type="pmid">20473734</pub-id></element-citation></ref><ref id="CR135"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Zhai</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Wan</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Shen</surname><given-names>F</given-names></name><name><surname>Ling</surname><given-names>C</given-names></name></person-group><article-title>Transarterial chemoembolization combined with Jie du granule preparation improves the survival outcomes of patients with unresectable hepatocellular carcinoma</article-title><source>Oncotarget.</source><year>2017</year><volume>8</volume><issue>28</issue><fpage>45234</fpage><lpage>45241</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.16804</pub-id><?supplied-pmid 28423370?><pub-id pub-id-type="pmid">28423370</pub-id></element-citation></ref><ref id="CR136"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murer</surname><given-names>F</given-names></name><name><surname>Pozzan</surname><given-names>C</given-names></name><name><surname>Peserico</surname><given-names>G</given-names></name><name><surname>Farinati</surname><given-names>F</given-names></name></person-group><article-title>Capecitabine in advanced hepatocellular carcinoma</article-title><source>Dig Liver Dis</source><year>2016</year><volume>48</volume><issue>10</issue><fpage>1260</fpage><lpage>1261</lpage><pub-id pub-id-type="doi">10.1016/j.dld.2016.06.037</pub-id><?supplied-pmid 27476466?><pub-id pub-id-type="pmid">27476466</pub-id></element-citation></ref><ref id="CR137"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Changou</surname><given-names>CA</given-names></name><name><surname>Shiah</surname><given-names>HS</given-names></name><name><surname>Chen</surname><given-names>LT</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Luh</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>SH</given-names></name><name><surname>Cheng</surname><given-names>YC</given-names></name><name><surname>Yen</surname><given-names>Y</given-names></name></person-group><article-title>A phase ii clinical trial on the combination therapy of phy906 plus capecitabine in hepatocellular carcinoma</article-title><source>Oncologist</source><year>2021</year><volume>26</volume><issue>3</issue><fpage>e367</fpage><lpage>e373</lpage><pub-id pub-id-type="doi">10.1002/onco.13582</pub-id><?supplied-pmid 33140457?><pub-id pub-id-type="pmid">33140457</pub-id></element-citation></ref><ref id="CR138"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Fahey</surname><given-names>P</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Ng</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>ZP</given-names></name><name><surname>Qiu</surname><given-names>Y</given-names></name><name><surname>Lai</surname><given-names>H</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name></person-group><article-title>A cohort study to examine the use of chinese herbal medicine in combination with conventional therapies for patients with hepatocellular carcinoma in China</article-title><source>Integr Cancer Ther</source><year>2018</year><volume>17</volume><issue>3</issue><fpage>902</fpage><lpage>911</lpage><pub-id pub-id-type="doi">10.1177/1534735418775819</pub-id><?supplied-pmid 29775121?><pub-id pub-id-type="pmid">29775121</pub-id></element-citation></ref><ref id="CR139"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>YH</given-names></name><name><surname>Lin</surname><given-names>CC</given-names></name><name><surname>Lai</surname><given-names>HC</given-names></name><name><surname>Chiang</surname><given-names>JH</given-names></name><name><surname>Lin</surname><given-names>JG</given-names></name><name><surname>Li</surname><given-names>TC</given-names></name></person-group><article-title>Adjunctive traditional Chinese medicine therapy improves survival of liver cancer patients</article-title><source>Liver Int</source><year>2015</year><volume>35</volume><issue>12</issue><fpage>2595</fpage><lpage>2602</lpage><pub-id pub-id-type="doi">10.1111/liv.12847</pub-id><?supplied-pmid 25875878?><pub-id pub-id-type="pmid">25875878</pub-id></element-citation></ref><ref id="CR140"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>JD</given-names></name><name><surname>Hainaut</surname><given-names>P</given-names></name><name><surname>Gores</surname><given-names>GJ</given-names></name><name><surname>Amadou</surname><given-names>A</given-names></name><name><surname>Plymoth</surname><given-names>A</given-names></name><name><surname>Roberts</surname><given-names>LR</given-names></name></person-group><article-title>A global view of hepatocellular carcinoma: trends, risk, prevention and management</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2019</year><volume>16</volume><issue>10</issue><fpage>589</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1038/s41575-019-0186-y</pub-id><?supplied-pmid 31439937?><pub-id pub-id-type="pmid">31439937</pub-id></element-citation></ref><ref id="CR141"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bahirwani</surname><given-names>R</given-names></name><name><surname>Reddy</surname><given-names>KR</given-names></name></person-group><article-title>Drug-induced liver injury due to cancer chemotherapeutic agents</article-title><source>Semin Liver Dis</source><year>2014</year><volume>34</volume><issue>2</issue><fpage>162</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1055/s-0034-1375957</pub-id><?supplied-pmid 24879981?><pub-id pub-id-type="pmid">24879981</pub-id></element-citation></ref><ref id="CR142"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>HQ</given-names></name><name><surname>Li</surname><given-names>HL</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Liang</surname><given-names>GW</given-names></name><name><surname>Huang</surname><given-names>XQ</given-names></name><name><surname>Huang</surname><given-names>ZQ</given-names></name><name><surname>Lang</surname><given-names>JM</given-names></name><name><surname>Zhang</surname><given-names>YP</given-names></name><name><surname>Chen</surname><given-names>XZ</given-names></name><name><surname>Chen</surname><given-names>YS</given-names></name></person-group><article-title>Treatment of middle/late stage primary hepatic carcinoma by Chinese medicine comprehensive therapy: a prospective randomized controlled study</article-title><source>Chin J Integr Med</source><year>2010</year><volume>16</volume><issue>2</issue><fpage>102</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1007/s11655-010-0102-3</pub-id><?supplied-pmid 20473733?><pub-id pub-id-type="pmid">20473733</pub-id></element-citation></ref><ref id="CR143"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Xiao</surname><given-names>XH</given-names></name></person-group><article-title>Integrative medicine in the era of cancer immunotherapy: Challenges and opportunities</article-title><source>J Integr Med</source><year>2021</year><volume>19</volume><issue>4</issue><fpage>291</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1016/j.joim.2021.03.005</pub-id><?supplied-pmid 33814325?><pub-id pub-id-type="pmid">33814325</pub-id></element-citation></ref><ref id="CR144"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cabrera</surname><given-names>R</given-names></name><name><surname>Singal</surname><given-names>AG</given-names></name><name><surname>Colombo</surname><given-names>M</given-names></name><name><surname>Kelley</surname><given-names>RK</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Mospan</surname><given-names>AR</given-names></name><name><surname>Meyer</surname><given-names>T</given-names></name><name><surname>Newell</surname><given-names>P</given-names></name><name><surname>Parikh</surname><given-names>ND</given-names></name><name><surname>Sangro</surname><given-names>B</given-names></name><name><surname>Reddy</surname><given-names>KR</given-names></name><name><surname>Watkins</surname><given-names>S</given-names></name><name><surname>Zink</surname><given-names>RC</given-names></name><name><surname>Di Bisceglie</surname><given-names>AM</given-names></name></person-group><article-title>A real-world observational cohort of patients with hepatocellular carcinoma: design and rationale for TARGET-HCC</article-title><source>Hepatol Commun</source><year>2021</year><volume>5</volume><issue>3</issue><fpage>538</fpage><lpage>547</lpage><pub-id pub-id-type="doi">10.1002/hep4.1652</pub-id><?supplied-pmid 33681685?><pub-id pub-id-type="pmid">33681685</pub-id></element-citation></ref><ref id="CR145"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mospan</surname><given-names>AR</given-names></name><name><surname>Morris</surname><given-names>HL</given-names></name></person-group><article-title>Fried MW Real-world evidence in hepatocellular carcinoma</article-title><source>Liver Int</source><year>2021</year><volume>41</volume><issue>S1</issue><fpage>61</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1111/liv.14864</pub-id><?supplied-pmid 34155788?><pub-id pub-id-type="pmid">34155788</pub-id></element-citation></ref></ref-list></back></article>